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’INTRODUCTION
Microtubules are key components of the cytoskeleton and are
involvedinawiderangeofcellularfunctions,notablycelldivision
wheretheyareresponsibleformitoticspindleformationandproper
chromosomal separation.
1 Consequently, microtubules have been
for the past decades important targets for the design and the
development of several potent natural and synthetic anticancer
drugs
2 such as paclitaxel,
3 epothilone A,
4 vinblastine,
5 and combre-
tastatin A-4
6(1, CA-4), molecules that are of utmost importance in
the management of cancers such as ovarian, breast, and prostate
cancers.
7,8 However, the eﬃcacy and the clinical usefulness of
currently available antimicrotubules is impeded by the occurrence
of chemoresistane, systemic toxicity, and poor biopharmaceutical
properties.
9,10 Therefore, thesearch for new antimicrotubuleagents
exhibiting improved biopharmaceutical proﬁles and pharmacody-
namics is the focus of numerous academic and industrial teams.
11
In the past decades, ligands to the colchicine-binding site (C-
BS) were extensively studied and many interesting compounds
were identiﬁed and tested. To that end, CA-4 isolated from the
bark of Combretum caﬀrum
12 was shown to exhibit potent
antiangiogenicandantitumoralactivies.However,poorsolubility
of the drug impinged its clinical development and required the
preparation of more soluble derivatives such as CA-4 phosphate
sodium salt
13 (2) and the amino acid hydrochloride salt
14 (3).
These molecules represent promising drugs in various clinical
settings, showing potent activities to disrupt vasculature and to
reduce signiﬁcantly the tumoral blood ﬂow.
15 Unfortunately,
CA-4,2, and 3 exhibit many deleterious eﬀects such as hyperten-
sion, hypotension, tachycardia, tumor pain, and lymphopenia.
16
In addition, the activity of CA-4, 2, and 3 is hampered by a short
biological half-life
17,18 and isomerization of their active cis-
stilbene conformation into the corresponding inactive trans
analogues.
13,19 To overcome the problem, the ethenyl bridge
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ABSTRACT:Sixty-onephenyl4-(2-oxoimidazolidin-1-yl)ben-
zenesulfonates (PIB-SOs) and 13 of their tetrahydro-2-oxopyr-
imidin-1(2H)-yl analogues (PPB-SOs) were prepared and
biologically evaluated. The antiproliferative activities of PIB-
SOs on 16 cancer cell lines are in the nanomolar range and
unaﬀected in cancer cells resistant to colchicine, paclitaxel, and
vinblastine or overexpressing the P-glycoprotein. None of the
PPB-SOs exhibit signiﬁcant antiproliferative activity. PIB-SOs
block the cell cycle progression in the G2/M phase and bind to
the colchicine-binding site on β-tubulin leading to cytoskeleton disruption and cell death. Chick chorioallantoic membrane tumor
assays show that compounds 36, 44, and 45 eﬃciently block angiogenesis and tumor growth at least at similar levels as
combretastatin A-4 (CA-4) and exhibit low to very low toxicity on the chick embryos. PIB-SOs were subjected to CoMFA and
CoMSIA analyses to establish quantitative structure activity relationships.4560 dx.doi.org/10.1021/jm200488a |J. Med. Chem. 2011, 54, 4559–4580
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of the stilbene moiety was converted into more biologically sta-
ble molecules utilizing polar groups such as carbonyl (e.g.,
phenstatin),
20 arylthioindole,
21 oxazole, triazole, and thiophene
bioisosteres.
22 In that context, Gweltaney et al. have successfully
converted the ethenyl group of CA-4 into the more stable and
more polar sulfonate group
23 (4).
N-Phenyl-N0-(2-chloroethyl)urea (CEU) is another class of
antimicrotubule agent characterized by its unique ability to
acylate Glu198 of β-tubulin, an amino acid located in a pocket
adjacent to the C-BS. The acylation of Glu198 leads to
microtubule depolymerization, hypoacetylation of Lys40 on
R-tubulin, cytoskeleton disruption, and anoikis.
24,25 CEU analo-
gues such as 1-(2-chloroethyl)-3-(4-iodophenyl)urea (5)
26 28
or1-(2-chloroethyl)-3-(3-(5-hydroxypentyl)phenyl)urea(6)
29 31
inhibit angiogenesis and tumor growth in three distinct animal
models.
25 The biodistribution of CEU analogues to organs of the
gastrointestinal tract suggests that they might be promising new
drugs for the treatment of colorectal cancers.
32,33 Several CEU
subsetswerealsofoundtobedevoidofantimicrotubuleaﬃnityand
to bind covalently to proteins such as thioredoxin isoform 1,
34 36
prohibitin 1,
37 and the mitochondrial voltage-dependent anion
channel 1.
38
’DESIGN OF SUBSTITUTED PHENYL (2-OXOIMIDA-
ZOLIDIN-1-YL)BENZENESULFONATES
Computational experiments conducted on antimicrotubule
CEU analogues led to the hypothesis that the N-phenyl-N0-(2-
chloroethyl)urea pharmacophore moiety of CEU might be a
bioisostericequivalenttothetrimethoxyphenylringofCA-4 and
severalotherdrugsbindingtotheC-BS.
39,40Thishypothesiswas
conﬁrmedbythesynthesisandbiologicalevaluationofmolecular
hybrids where the trimethoxyphenyl moiety of CA-4 was re-
placedbythepharmacophoremoietyofCEUtogivecompounds
suchas1-(4-(3-hydroxy-4-methoxystyryl)phenyl)-3-(2-chlor-
oethyl)urea (7).
41 Several of these molecular hybrids exhibited
antiproliferative activity through the acylation of Glu198 as
observed with the original CEU. Subsequently, we initiated the
developmentofnewCEUanaloguesincorporatingthemolecular
scaﬀold of CA-4 to enhance eﬃcacy, stability, and polarity. We
prepared new molecular hybrids based on the conversion of the
trimethoxyphenyl ring of compound 4 into an N-phenyl-N0-(2-
chloroethyl)urea moiety to generate several CEU-sulfonate
analogues (8). A number of 8 derivatives exhibited cytocidal
activity at the micromolar level on several tumor cell lines and
generally blocked the cell cycle progression in the G2/M phase.
We previously showed that the cyclization of the 2-chloroethy-
lurea moiety of CEU into 4,5-dihydrooxazol-2-amine derivatives
improved the cytocidal activity of CEU.
34,36,42 On the basis of
these results, we hypothesized that the cyclization of the N-
phenyl-N0-(2-chloroethyl)urea moiety of 8 might also be bene-
ﬁcial to the antiproliferative activity.
In this study, we described the preparation and the evaluation
of new phenyl 4-(2-oxoimidazolidin-1-yl)benzenesulfonate deri-
vatives (PIB-SOs) as antiproliferative agents targeting the C-BS.
We assessed the eﬀect of the nature and the position of the
substituents on the aromatic ring B (PIB-SOs 9 68) on the
antiproliferative activity, on the binding to the C-BS, and on the
antineoplastic and toxic activities on human cancer cells grafted
onto the chick chorioallantoic membrane tumor (CAM) assays.
Thirteen of the most potent PIB-SO derivatives were used to
evaluate the eﬀect on the aforementioned parameters of enlar-
gingtheimidazolidin-2-one ringofPIB-SOintoatetrahydropyr-
imidin-2(1H)-one ring (PPB-SOs 69 81) (Figure 1).
’RESULTS
Chemistry. Initially, 8 derivatives were prepared as follows.
4-Nitrodiphenylsulfonates were obtained by nucleophilic addi-
tion of the appropriate phenol to 4-nitrophenylsulfonyl chloride
followed by the reduction of the nitro group into its aniline. The
relevant anilines were then added to 2-chloroethyl isocyanate to
yield the corresponding 8 derivatives. Finally, PIB-SOs 9 14
were prepared from the catalytic cyclization of the CEU sulfo-
natesin thepresence of KFadsorbedon Al2O3 (4:6) inrefluxing
acetonitrile (Scheme 1).
The aforementioned preparation of 8 derivatives was a long
and tedious process. Therefore, we used an easier and more
eﬃcient approach for the synthesis of PIB-SOs and PPB-SOs
9 81 (Scheme 2)
43,44 based on the nucleophilic addition of
aniline to either 2-chloroethyl isocyanate or 3-chloropropyl isocya-
nate in methylene chloride at 25  C followed by cyclization into
the corresponding 1-phenylimidazolidin-2-one (84) or tetrahy-
dro-3-phenylpyrimidin-2(1H)-one(85)usingsodiumhydridein
THFat25  C. Compound84was also prepared using triphosgene,
Figure 1. Structures of CA-4 and 2 81.4561 dx.doi.org/10.1021/jm200488a |J. Med. Chem. 2011, 54, 4559–4580
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N-phenylethylenediamine, andtriethylamineinanhydrous tetra-
hydrofuran at 0  C. 4-(2-Oxoimidazolidin-1-yl)benzene-1-sulfo-
nylchloride(86) and4-(tetrahydro-2-oxopyrimidin-1(2H)-yl)ben-
zene-1-sulfonylchloride(87)wereobtainedbychlorosulfonationof
84 and 85 by chlorosulfonic acid in carbon tetrachloride at 0  C.
Compounds 9 81 were synthesized by nucleophilic addition of
an appropriate phenol on either compound 86 or 87 in the
presenceoftriethylamineinmethylenechlorideat25 C.Aniline
40, 51, and 63 were obtained by the reduction of the nitro group
on39,50,and62underhydrogenatmosphereinthepresenceof
palladium on charcoal in ethanol. Phenol 14 was obtained by
deprotection ofthetert-butyldimethylsilylintermediate58inthe
presence of tributylammonium ﬂuoride in THF.
Evaluation of the Antiproliferative Activity. The antiproli-
ferative activity of PIB-SO and PPB-SO derivatives was assessed on
threehumancancercelllines,namely,HT-29coloncarcinoma,M21
skin melanoma, and MCF7 breast carcinoma cells. These cell lines
wereselected,astheyaregoodrepresentativesoftumorcellsorigina-
ting from the three embryonic germ layers. Cell growth inhibition
was assessed according to the NCI/NIH Developmental Therapeu-
ticsProgram.
45TheresultsaresummarizedinTable1andexpressed
as the concentration of drug inhibiting cell growth by 50% (IC50).
Scheme 2
a
aReagentsandconditions:(i)2-chloroethylisocyanateor3-chloropropylisocyanate,DCM;(ii)NaH,THF;(iii)triphosgene,TEA,THF;(iv)ClSO3H,
CCl4; (v) relevant phenol, triethylamine, DCM; (vi) H2, Pd/C 10%, EtOH; (vii) TBAF, THF.
Scheme 1
a
aReagents and conditions: (i) Al2O3/KF, CH3CN.4562 dx.doi.org/10.1021/jm200488a |J. Med. Chem. 2011, 54, 4559–4580
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Table 1. Evaluation of the Antiproliferative Activity of PIB-SOs, PPB-SOs, CA-4, and Compound 6 on HT-29, M21, and MCF7
Cells
aThe dash ( ) indicates “not applicable”.
bIC50 is expressed as the concentration of drug inhibiting cell growth by 50%.4563 dx.doi.org/10.1021/jm200488a |J. Med. Chem. 2011, 54, 4559–4580
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Table 2. Eﬀects of the Most Potent PIB-SOs, CA-4, and Compound 6 on Cell Cycle Progression, Cytoskeleton Integrity, and
Results of a Competition Assay with EBI4564 dx.doi.org/10.1021/jm200488a |J. Med. Chem. 2011, 54, 4559–4580
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MechanismofAction.CA-4andcompounds2 7areknown
C-BS antagonists, disrupting the polymerization of tubulin hetero-
dimers, inhibiting cell cycle progression in the G2/M phase, and
leading to anoikis.Therefore, we have conducted experiments to
identify the mechanism involved in the cytocidal activity of PIB-
SOs in relation to their expected binding to the C-BS on
β-tubulin. The evaluation was conducted using compounds 9 12,
16, 17, 19 22, 24 28, 30, 31, 33 39, 41 49, 53, 55, 56, 59,
60, and 65 that were exhibiting IC50 lower than 100 nM in M21
tumor cells. We first assessed their effects on cell cycle progres-
sion.Table2showsthepercentage ofM21 cellsinG0/G1,S,and
G2/MphasesaftertreatmentwiththeselectedPIB-SOstogether
with CA-4 and compound 6 at 5 times their respective IC50.
Afterward, we assessed the binding of these compounds to the
colchicine-binding site. To that end, we developed a quick and
simple detection procedure based on the competition between
the bisthioalkylation of Cys239 and Cys354 by N,N0-ethylene-
bis(iodoacetamide) (EBI) and drugs binding to the C-BS to
assesstheabilityofanti-C-BSagentstooccupythatbindingsite.
46
Briefly, the β-tubulin adduct formed by the covalent binding of EBI
on Cys239 and Cys354 is easily detectable by Western blot as an
immunoreacting band of β-tubulin migrating faster than the
native β-tubulin. The occupancy of the C-BS by relevant anti-
mitotics inhibits the formation of the EBI/β-tubulin adduct,
resulting in an assay that allows the easy and inexpensive
screening of new molecules targeting the C-BS. Table 2 shows
aForcellcycleprogression, M21cellswereincubated inpresenceofPIB-SOsat5timestheir respectiveIC50for24h.
bForcompetitionassaywithEBI,
MDA-MB-231 cells were incubated in the presence ofPIB-SOs at1000 times their respective IC50 for2 h andafterward in the presence of100 μM EBI
for1.5 h.
cInhibitioncoding:þþþ,stronginhibition;þþ,signiﬁcantinhibition;þ,weakinhibition; ,noinhibition;N/A,notapplicable.
dM21cells
weretreatedfor16hwiththedrugat5timestheirrespectiveIC50,andcellularmicrotubulestructureswerevisualizedusingindirectimmunoﬂuorescenceusing
an anti-β-tubulin monoclonal antibody.
Table 2. Continued4566 dx.doi.org/10.1021/jm200488a |J. Med. Chem. 2011, 54, 4559–4580
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the results obtained from the competition between EBI at 100
μM andPIB-SOs 9 12, 16, 17, 19 22,24 28,30,31,33 39,
41 49, 53, 55, 56, 59, 60, and 65 at 1000 times their respective
IC50onMDA-MB-231cells.Finally,theeffectofPIB-SOsonthe
cytoskeleton was also visualized using a fluorescent anti-β-
tubulinantibodyandimmunofluorescencetechniques(Table2).
Antiproliferative Activity of PIB-SOs on Chemoresistant
and Wild-Type Cancer Cells. The antiproliferative activity of
compounds 12, 26, 31, 35, 36, 38, 44 46, and 60 was assessed
on10wild-typecancerandthreechemoresistantcelllines(Tables3
and 4). Wild-type cancer cell lines were Chinese hamster ovary
CHO, human chronic myelogenous leukemia K562, murine
lymphocytotic leukemia L1210, murine macrophages P388D1,
murine melanoma B16F0, human prostate carcinoma DU 145,
human fibrosarcoma HT-1080, human breast adenocarcinoma
MDA-MB-231, human ovarian SKOV3, and T cell leukemia
CEM cells. Chemoresistant cancer cells were paclitaxel-resistant
CHO-TAX 5-6
47 colchicine- and vinblastine-resistant CHO-VV
3-2,
48 and multidrug-resistant leukemia CEM-VLB
49,50 cells.
Colchicine,
51 paclitaxel, and vinblastine were used as positive con-
trols. The concentration of drug inhibiting cell growth by 50% is
expressedastheIC50.Cellgrowthinhibitionwasassessedaccording
to the NCI/NIH Developmental Therapeutics Program.
45
CAMAssay.HumanHT-1080fibrosarcomacellsweregrafted
onto the chorioallantoic membrane of fertilized chick eggs to
assess the antitumoral and the antiangiogenic/antivasculogenic
activityofcompounds12,26,31,35,36,38,44,45,46,and60in
the CAM assay (Figure 2). The results shown in Figure 2 were
obtained from two independent experiments using at least 10
eggs per experiment. No related toxicity was observed on chick
embryos treated with the excipient. Untreated eggs were used as
negative controls and for normalization of the results. The drugs
Table 3. Antiproliferative Activity of Compounds 12, 26, 31, 35, 36, 38, 44 46, 60, Colchicine, Paclitaxel, and Vinblastine on
CHO, K562, L1210, P388D1, B16F0, DU-145, HT-1080, MDA-MB-231, SKOV3, and CEM Cells
IC50 (nM)
d
compd CHO K562 L1210 P388D1 B16F0 DU 145 HT-1080 MDA-MB-231 SKOV3 CEM
12 240 240 250 260 510 650 240 760 320 250
26 18 18 21 19 49 57 24 69 29 19
31 73 65 67 76 91 170 65 100 72 68
35 32 18 19 20 65 72 34 55 42 20
36 18 16 17 19 46 58 19 45 22 17
38 17 14 19 18 30 57 19 48 23 17
44 7.3 7.5 6.4 7.8 25 25 8.2 14 6.8 7.1
45 7.4 2.5 5.4 2.7 9.2 8.5 5.9 9.4 6.1 7.1
46 17 7.2 9.6 7.4 41 66 18 26 16 16
60 230 180 140 240 250 550 190 360 210 200
Col
a 220 6.8 6.9 28 13 10 1.1 2.9 2.1 7.9
Pac
b 170 0.71 0.40 35 28 1.3 0.15 9.1 2.6 0.27
Vbl
c 17 0.36 0.16 1.8 0.099 0.063 0.099 0.12 0.039 0.38
aCol, colchicine.
bPac, paclitaxel.
cVbl, vinblastine.
dIC50: concentration of drug inhibiting cell growth by 50%.
Table 4. Antiproliferative Activity of Compounds 12, 26, 31, 35, 36, 38, 44 46, 60, Colchicine, Paclitaxel, and Vinblastine on
Chemoresistant TAX 5-6, CHO-VV 3-2, and CEM-VLB Cells
compd
IC50 (nM)
d
CHO-TAX 5-6
e
ratio resistant/wild-type
CHO-TAX 5-6/CHO
IC50 (nM)
d
CHO-VV 3-2
f
ratio resistant/wild-type
CHO-VV 3-2/CHO
IC50 (nM)
d
CEM-VLB
g
ratio resistant/wild-type
CEM-VLB/CEM
12 200 0.83 250 1.0 320 1.3
26 14 0.78 21 1.2 23 1.2
31 38 0.52 74 1.0 87 1.3
35 12 0.38 39 1.2 32 1.6
36 9.3 0.52 20 1.1 20 1.2
38 8.9 0.52 20 1.2 18 1.1
44 5.2 0.71 15 2.1 9.2 1.3
45 3 0.41 8.2 1.1 9.5 1.3
46 6.1 0.36 20 1.2 19 1.2
60 86 0.37 260 1.1 270 1.4
Col
a 140 0.64 620 2.8 360 46
Pac
b 520 3.1 140 0.82 3340 12370
Vbl
c 6.9 0.41 66 3.9 600 1579
aCol,colchicine.
bPac,paclitaxel.
cVbl,vinblastine.
dIC50:concentrationofdruginhibitingcellgrowthby50%.
ePaclitaxel-resistantCHO-TAX5-6cells.
fColchicine-and vinblastine-resistant CHO-VV 3-2 cells.
gMultidrug-resistant leukemia CEM-VLB cells.4567 dx.doi.org/10.1021/jm200488a |J. Med. Chem. 2011, 54, 4559–4580
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were administered iv at 3 μg per egg except for compounds 12
and 45, which were injected at 10 and 1 μg per egg, respectively.
Finally, CA-4 was used as positive control and was administered
iv at 1 and 3 μg per egg.
Comparative Molecular Field and Comparative Molecular
Similarity Indices Analyses (CoMFA and CoMSIA) of PIB-SOs
andPPB-SOs.CoMFAandCoMSIAanalyseswereconductedto
establish quantitative structure activity relationships ruling the
antiproliferative activity of PIB-SOs, to understand the mechan-
isms underlying the binding of PIB-SOs to the C-BS, and to
design new and more selective C-BS antagonists. From compu-
tational experiments, we developed 3D quantitative structure 
activity relationships (3D-QSAR) models. To that end, we used
Surflex-Sim which is a 3D molecular similarity optimization and
searching program that uses a morphological similarity function
and fast pose generation based similarity on a molecule’s shape,
hydrogen bonding, and electrostatic properties techniques to gen-
erate alignments of molecules.
52 Surflex-Sim algorithm was ex-
pected to reduce the impact of factors of uncertainty during the
generation of the QSAR models. The multiple alignments of
most of the active compounds gave the best description of the
positions of functional groups leading to the hypothesis genera-
tion. Underlying assumption in the alignment is that the com-
pound with better fit to the hypothesis on structural alignment
would have better activity. At first, a mutual alignment of the
most potent compounds was performed to find a superposition
of all input molecules that maximizes the similarity and mini-
mizes the overall volume of the superposition. A hypothesis was
generated from this superposition, and that hypothesis will be
used as a template to align the set of active molecules. Then the
alignment of the data set will be used to generate QSAR models.
Compounds26and45werechosentogeneratehypothesisusing
SYBYL Surflex-Sim mutual alignment module. The alignment
hypothesis shows that the groups of same property are well
aligned (Figure 3A). Then all PIB-SOs and PPB-SOs were super-
posed on to the alignment hypothesis using Surflex-Sim flexible
superposition module (Figure 3B).
From the q
2 and r
2
cv values, the analysis that includes the
similarity data to the hypothesis improved the r
2
cv in both CoMFA
and CoMSIA models (models A, B, C vs models D, E, F, models
G, H, I vs models J, K, L). All three antiproliferative activities in
HT-29, M21, and MCF7 cell lines were then used as dependent
variables to build CoMSIA and CoMFA models. The optimized
parameters and the statistical data in the PLS analysis of six
CoMSIA models and six CoMFA models are listed in Tables 5
and 6.
’DISCUSSION
PIB-SOs Exhibit Potent Antiproliferative Activity on
Tumor Cells.PIB-SO and PPB-SO derivatives were divided into
four subgroups based on IC50: (1) strong IC50 ranging from 4 to
10nM(44and45);(2)goodIC50rangingfrom8.2to60nM(9,
24 26, 28, 30, 31, 33 38, 41, 42, 46, 48, and 55); (3) fair IC50
ranging from 24 to 220 nM (10 12, 16 22, 27, 29, 39, 43, 47,
49, 50, 52, 53, 56, 59 61, and 65); (4) weak IC50 ranging from
128to>1000nM(14,15,23,32,40,51,54,57,58,62 64,and
66 81). Compounds 44 and 45 are almost equipotent to
combretastatin A-4, which is almost 1000-fold higher than
previous CEU derivatives. Table 3 shows that compounds 12,
26, 31, 35, 36, 38, 44 46, and 60 are also very potent against
CHO, K562,L1210, P388D1,B16F0,DU145,HT-1080,MDA-
MB-231, SKOV3, and CEM cells.
Antiproliferative Activity of PIB-SOs on Chemoresistant
Tumor Cells. Table 4 shows the antiproliferative activities of
PIB-SOs 12, 26, 31, 35, 36, 38, 44 46, and 60 on drug-resistant
cell lines CHO-TAX 5-6, CHO-VV 3-2, and CEM-VLB. On one
hand,CHO-TAX5-6cellsareresistanttomicrotubulestabilizers
(e.g., paclitaxel) and hypersensitive to microtubule disruptors
(e.g., colchicine, vinblastine), while CHO-VV 3-2 cell line are
resistant to microtubule disruptors and hypersensitive to micro-
tubulestabilizers.
48Ontheotherhand,CEM-VLBcellsoverexpress
Figure 2. Eﬀect of compounds 12, 26, 31, 35, 36, 38, 44 46, 60, and
CA-4 on HT 1080 tumor growth and embryo’s toxicity using the CAM
model. Gray bars represent the percentage of tumor-wet weight of
tumors treated with and without excipient. Black bars represent the
percentage of chick embryo mortality.
Figure 3. (A) Alignment hypothesis generated using Surﬂex-Sim
mutual alignment module from compounds 26 and 45. (B) Super-
position of the derivatives of PIB-SOs and PPB-SOs onto the alignment
hypothesis.4568 dx.doi.org/10.1021/jm200488a |J. Med. Chem. 2011, 54, 4559–4580
Journal of Medicinal Chemistry ARTICLE
P-glycoprotein
53 which is responsible for the cellular efflux of
drugs and chemoresistance to anticancer drugs such as doxor-
ubicin, etoposide, paclitaxel, and vinblastine.
54 As expected and
shown in Table 4, CHO-TAX 5-6 cells that are resistant to
paclitaxel were sensitive to PIB-SOs, colchicine, and vinblastine.
Besidecompound 44, CHO-VV 3-2 cells that are resistant to the
colchicine and vinblastine were sensitive to paclitaxel and were
unexpectedly sensitive to PIB-SOs. Finally, CEM-VLB cells that
are46-,12370-,and1579-foldresistanttothecolchicine,vinblastine,
andpaclitaxel,respectively,werestillsensitivetoPIB-SOs.These
results demonstrate the insensitivity of the antiproliferative activity
ofPIB-SOstotubulinmutationsandP-glycoproteinoverexpression.
PIB-SOs Arrest Cell Cycle Progression in G2/M Phase.
Table 2 shows the percentage of M21 cells exhibiting arrest of
the cell cycle progression in G0/G1, S, and G2/M phases,
respectively, after treatment with PIB-SOs for 24 h at 5 times
their respective IC50. Control cells treated with 0.5% of DMSO
werefoundtobeinG0/G1,S,andG2/Mphasesat61%,30%,and
9%, respectively. Incubation with compounds 9, 11, 12, 19 22,
24, 26, 27, 30, 31, 33, 35-38, 41, 43, 44, 46 49, 53, 55, 56, and
65 strongly blocked the cell cycle in G2/M phase; the number of
cells in G2/M phase increased by 39 86%. Compounds 10, 16,
17, 25, 28, 34, 42, 45, and 59 blocked almost exclusively the cell
cycle in G2/M phase, which is similar to the effect of CA-4.
PIB-SOsInhibitEBIBindingtotheColchicine-BindingSite.
C-BS antagonists such as colchicine, podophyllotoxin,
55 2-me-
thoxyestradiol,
56,57andCA-4inhibittheEBIbindingtoβ-tubulin
leading to the disappearance of the β-tubulin EBI adduct formed
and detectable by Western blot as a second immunoreacting
band of β-tubulin migrating faster than the native β-tubulin.
46
Control cells treated with 0.5% DMSO followed by EBI show an
intense β-tubulin EBI adduct band. With the exception of
compound 11, all PIB-SO inhibited the EBI binding to the
C-BS. As depicted in Table 2, compounds 12, 17, 25, 33, 47, 49,
53, 55, and 56 weakly interacted with the C-BS. However,
compounds 9, 21, 27, 30, 37, and 60 strongly inhibit the
formation of the β-tubulin EBI adduct and compounds 10,
16,19,20,22,24,26,28,31,34 36,38,39,41 46,48,59,and
Table 5. Statistical Data of QSAR Method with CoMSIA against Antiproliferative Activity on HT-29, M21, and MCF7 Cells
CoMSIA 1 CoMSIA 2
model A
a (HT-29) model B
a (M21) model C
a (MCF7) model D
a (HT-29) model E
a (M21) model F
a (MCF7)
ﬁelds and
parameters
b
CoMSIA FF, similarity,
IM2, LogP, MW
CoMSIA FF, similarity,
IM2, LogP, MW
CoMSIA FF, similarity,
IM2, LogP, MW
CoMSIA FF, MR CoMSIA FF, MR CoMSIA FF, MR
q
2 c 0.684 0.660 0.670 0.618 0.619 0.569
r
2
cv
d 0.697 0.668 0.680 0.612 0.609 0.551
STEPloo
e 0.520 0.541 0.518 0.584 0.579 0.601
ONC
f 6 6 6 666
SEENoValidation
g 0.350 0.352 0.352 0.308 0.302 0.318
r
2 0.863 0.859 0.852 0.893 0.896 0.879
F
h 71.406
(n1 = 6, n2 = 68)
95.801
(n1 = 6, n2 = 68)
70.591
(n1 = 6, n2 = 68)
94.985
(n1 = 6, n2 = 68)
97.938
(n1 = 6, n2 = 68)
82.390
(n1 = 6, n2 = 68)
aModels A, B, and C are optimized CoMSIA models with similarity descriptor. Models D, E, and F are CoMSIA models without similarity descriptor.
bCoMSIA FF: steric, electrostatic, hydrophobic, donor, acceptor.
cq
2 = cross-validated correlation coeﬃcient from LOO.
dr
2
cv = cross-validated
correlation coeﬃcient (10 groups).
eSTEP = standard error ofprediction.
fONC =optimal number of components.
gSEE =standard error of estimate.
hF = r
2/(1   r
2).
Table 6. Statistical Data of QSAR Method with CoMFA against Antiproliferative Activity on HT-29, M21, and MCF7 Cells
CoMFA 1 CoMFA 2
model G
a (HT-29) model H
a (M21) model I
a (MCF7) model J
a (HT-29) model K
a (M21) model L
a (MCF7)
ﬁelds and
parameters
b
CoMFA FF,
similarity, MW
CoMFA FF,
similarity, MW
CoMFA FF,
similarity, MW
CoMFA FF, LogP CoMFA FF, LogP CoMFA FF, LogP
q
2 c 0.667 0.632 0.643 0.538 0.539 0.513
r
2
cv
d 0.662 0.617 0.638 0.503 0.512 0.473
STEPloo
e 0.537 0.561 0.539 0.637 0.632 0.634
STEPcv
e 0.541 0.573 0.543 0.661 0.651 0.660
ONC
f 444 555
SEENoValidation
g 0.368 0.370 0.378 0.326 0.321 0.340
r
2 0.844 0.840 0.824 0.879 0.882 0.860
F
h 94.467
(n1 = 4, n2 = 70)
91.731
(n1 = 4, n2 = 70)
82.105
(n1 = 4, n2 = 70)
100.253
(n1 = 5, n2 = 69)
102.718
(n1 = 5, n2 = 69)
84.958
(n1 = 5, n2 = 69)
aModels G, H, and I are optimized CoMFA models with similarity descriptor. Models J, K, and L are CoMFA models without similarity descriptor.
bCoMFA FF: steric, electrostatic.
cq
2 = cross-validated correlation coeﬃcient from LOO.
dr
2
cv = cross-validated correlation coeﬃcient (10 groups).
eSTEP = standard error of prediction.
fONC = optimal number of components.
gSEE = standard error of estimate.
hF = r
2/(1   r
2).4569 dx.doi.org/10.1021/jm200488a |J. Med. Chem. 2011, 54, 4559–4580
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65 abrogate its formation as CA-4 does, suggesting that these
molecules are strongly binding to the C-BS and that they act as
antimitotics.
PIB-SOs Disrupt the Cytoskeleton of Tumor Cells. Table 2
shows the cytoskeleton of M21 cells treated with PIB-SO at 5
times their respective IC50. The cytoskeleton of control M21
cells treated with DMSOis homogeneous and linear and forms a
structured network, while all the cytoskeleton of M21 cells
treatedwiththe41PIB-SOstestedsofarclearlyexhibitdisrupted
microtubular structures.
PIB-SOs Inhibit the Growth of Solid Tumors in the CAM
Assay. The growth of solid tumors on the surface of the
chorioallantoic membrane depends on the ability of the grafted
tumor cells to stimulate angiogenesis and to grow significantly
within a 7-day period. HT-1080 human fibrosarcoma cells were
used because they produce solid tumors that are sensitive to
antiangiogenicandantitumoraldrugs.
25,58 61AsshowninFigure2,
the excipient was well tolerated by chick embryos when com-
pared to control embryos (10% and 4% mortality, respectively).
The selected drugs were tested at 3 μg of drug per egg with the
exception of compounds 12 and 45 which were tested also at 10
and 1 μg per egg, respectively. CA-4 was tested at 1 and 3 μg per
egg and was used as a positive control exhibiting a strong anti-
vasculogenic activity inhibiting tumor growth by 48% and 45%,
respectively.CA-4exhibited toxicityon chick embryos(18% and
41% mortality, respectively). Compounds 46 and 60 had no
significant inhibitory effect on the growth of tumors, and both
showed lethal toxicity on 29% of the embryos. Compounds 12,
26,31,and35weaklyinhibitedthegrowthoftumor andshowed
low toxicity (13 15% mortality of embryos). Compounds 36,
44, and 45 had good inhibition of the tumor growth higher than
or similar to that of CA-4 (46%, 56%, and 39% reduction
compared to controls) with almost no toxicity (0%, 10%, and
8%mortality,respectively).Finally,compound38stronglyinhibited
the growth of tumor but was toxic on 43% of the embryos.
CoMSIA Models. In all CoMSIA models, the contour map of
each field has similar coverage areas for different biological
activities. For example, in the contour map including HT-29,
the optimized CoMSIA models included descriptors of molec-
ular similarity (to the alignment hypothesis), molecular weight,
CLogP, and the index of imidazolidin-2-one and the tetrahy-
dropyrimidin-2(1H)-one rings (PIB-SOs and PPB-SOs). The
model indicates that PIB-SOs are more preferred to contribute
toward higher activity. Models without molecular similarity
descriptor (models D, E, and F) had lower r
2 in both LOO
analysis and cross-validation analysis. This indicates that the
alignment hypothesis is reliable and the molecular similarity
descriptor is required for a successful model generation. The
predicted PIB-SO molecular activities of models A, B, and C are
listed in Table 2 in Supporting Information.
In the set of PIB-SO molecules, the most varied position is on
thephenylringB,sothefollowing discussion wouldfocusonthe
substitute position on this phenyl ring. Figure 4A shows the
favored and disfavored areas of steric ﬁeld. Most of the area
surrounding the molecule was infavor of steric ﬁeld. Thus, bulky
groups have positive contributions to the biological activity on
the phenyl group at positions 2, 3, 5, and 6. Bulky groups at
position 4 have negative contribution to the biological activity.
That explains why most of the compounds 52 63 have bulky
substitutes on 4 positions and have lower biological activities.
The eﬀects of electrostatic ﬁeld are shown in Figure 4B. As
depicted in the ﬁgure, in the area around position 3 of the
aromatic ring B electronegative groups increase biological activ-
ity while the electropositive group contributes to higher biolo-
gical activity at positions 4 and 5. The hydrophobicity
contributions are shown in Figure 4C. The most favorable areas
Figure4. ContourmapsofCoMSIAﬁeldscontributingtoligandbindinggeneratedbyPLSanalysisinmodelA(HT-29).Compound45(ball-and-stick
model) was shown in the ﬁgure as a reference to depict the ﬁeld region. (A) Contour map of steric ﬁeld. Green areas present favored steric groups, and
yellow areas present disfavored steric groups. (B) Contour map of electrostatic ﬁeld. Blue areas favored electrostatic ﬁeld (higher positive charge will
increasetheactivity)andredareasdisfavoredelectrostaticﬁeld(lowerpositivechargewillincreasetheactivity).(C)Contourmapofhydrophobicﬁeld.
Yellow areas show favored hydrophobic region, and cyan areas show disfavored hydrophobic region. (D) Contour map of hydrogen bond donor ﬁeld.
Cyan regions are the hydrogen bond donor preferred region, and purple regions are where hydrogen bond donor is not favored. (E) Contour map of
hydrogen bond acceptor ﬁeld. Magenta regions depict the favored hydrogen bond acceptor region, and red regions illustrate the hydrogen bond
disfavored region.4570 dx.doi.org/10.1021/jm200488a |J. Med. Chem. 2011, 54, 4559–4580
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forhydrophobicmoietiesarearoundposition4andtheareasof5
and 6 positions. In the back and far end of 4 substitute positions,
hydrophobic groups are not suggested. In Figure 4D, there is a
very small area on the 5 substituted position that is a hydrogen
bond donor preferring area (cyan color). Hydrogen bond donor
was not preferred in most of the regions around 3-, 4-, and
5-substituted position (purple color). Hydrogen bond acceptor
is favored in the area of sulfonate oxygen on one side of the
phenyl ring (magenta color in Figure 4E). On the other side of
the end group phenyl ring, around the 1 position and between 4
and 5 substituted positions are the regions for which hydrogen
bond acceptor is not suggested for high biological activity (red
color in Figure 4E).
CoMFAModels.InCoMFAmodels,wehaveincludedHT-29
activity as an example to illustrate the results shown in Figure 5.
Optimized QSAR models included CoMFA fields, molecular
similarity data to the hypothesis, and molecular weight. Same as
CoMSIAmodels,molecularsimilaritydescriptor (to thehypoth-
esis) contributes to the successful QSAR models. The predicted
PIB-SO molecular activities of models G, H, and I are listed in
Table 3 in Supporting Information.
SimilartotheresultsobtainedfromCoMSIAmodels,CoMFA
models also suggested that most areas in front (the viewer side)
of the phenyl ring B prefer abulky grouptomake inhibitorshave
high biological activity (Figure 5A). But CoMFA models did not
suggest the disfavored area around the 4-substituted position on
the phenyl ring. There are additional areas that CoMFA models
suggesttoavoidtheintroductionofbulkygroups,about2Åaway
from positions 2 and 3 of the imidazolidone ring. In Figure 5B,
the favored electropositive region is much bigger than in the
CoMSIA model, which covers the top and front (viewer’s side)
regionsof4-and5-substitutedpositionsofthephenylring.Inthe
back of the phenyl ring (away from viewer’s side), substituted 3,
4, and 5 positions of the phenyl ring preferred to have electro-
negativegroups.Thisareaisalsolargerthantheareasuggestedin
CoMSIA models.
’CONCLUSIONS
We have identiﬁed a novel class of antimicrotubule agents
designated as substituted phenyl 4-(2-oxoimidazolidin-1-yl)ben-
zenesulfonates(PIB-SOs)thatbindtotheC-BSontubulin.PIB-
SOs were designed as hybrid entities between CEU and CA-4
analogues where the N-phenyl-N0-(2-chloroethyl)urea pharma-
cophore was cyclized into a new 1-phenylimidazolidin-2-one
pharmacophoric scaﬀold. PIB-SOs were synthesized in fair to
good yields. They exhibit antiproliferative activities in the lower
nanomolar range on 16 cancer cell lines and arrest the cell cycle
progression in the G2/M phase. Minor structural modiﬁcations
such as expanding the ﬁve-member imidazolidin-2-one ring into
the six-member tetrahydropyrimidin-2(1H)-one ring led to a
dramatic decrease of the antiproliferative activity, indicating the
sensitivity of the new pharmacophore to modiﬁcations. Compe-
tition assays using EBI and immunoﬂuorescence using anti-β-
tubulinantibodyconﬁrmedthatPIB-SOsarepotentantimitotics
bindingtotheC-BS.Inaddition,thecytotoxicityofPIB-SOswas
notaﬀectedincellsresistanttocolchicine,paclitaxel,andvinblastine
and overexpressing the P-glycoprotein. Finally, PIB-SOs 36, 44,
and 45 have exhibited potent antitumoral and antiangiogenic
activities in the CAM assay that are at least as good as CA-4 but
exhibited also a lower toxicity than CA-4 on chick embryos, sug-
gesting these molecules as promising anticancer drugs.
’EXPERIMENTAL SECTION
Biological Methods. Cell Lines Culture. HT-29 human colon
carcinoma, MCF7 human breast carcinoma, MDA-MB-231 human
breast carcinoma, HT-1080 human fibrosarcoma, K562 human chronic
myelogenous leukemia, L1210 murine lymphocytotic leukemia, P388D1
murine macrophages, B16F0 murine melanoma, DU 145 human prostate
carcinoma, and SKOV3 human ovarian were purchased from the
American Type Culture Collection (Manassas, VA). Chinese hamster
ovary cells (CHO), colchicine- and vinblastine-resistant CHO-VV 3-2
cells, and paclitaxel-resistant CHO-TAX 5-6 cells were generously
provided by Dr. Fernando Cabral (University of Texas Medical School,
Houston, TX).
47,48 T cell leukemia CEM cells and multidrug-resistant
leukemia CEM-VLB were generously provided by Dr. William T. Beck
(University of Illinois at Chicago, College of Pharmacy, IL).
49 M21
human skin melanoma cells were provided by Dr. David Cheresh
(University of California, San Diego School of Medicine, CA). B16F0,
DU 145, HT-29, HT-1080, M21, MCF7, MDA-MB-231, and SKOV3
cells were cultured in DMEM medium containing sodium bicarbonate,
high glucose concentration, glutamine, and sodium pyruvate (Hyclone,
Logan, UT) supplemented with 5% of calf serum. CHO, CHO-VV 3-2,
CHO-TAX5-6,CEM,CEM-VLB,K562,L1210,andP388D1cellswere
cultured in RPMI medium (Hyclone, Logan, UT) supplemented with
10% of calf serum. The cells were maintained at 37  C in a moisture-
saturated atmosphere containing 5% CO2.
AntiproliferativeActivityAssay.Theantiproliferativeactivityof
PIB-SOs (9 68) and PPB-SOs (69 81) was assessed using the pro-
cedure described by the National Cancer Institute for its drug screening
program with slight modifications.
45The 96-well microtiter plates were
seededwith75μLoftumorcell(forHT-29,5000cells;M21,3500cells;
MCF7,7500cells;CHO,1000cells;K562,5000cells;L1210,6000cells;
P388D1, 18000 cells; B16F0, 2000 cells; DU 145, 5000 cells; HT-1080,
3000 cells; MDA-MB-231, 3000 cells; SKOV3, 5000 cells; CEM, 20000
cells; CHO-VV 3-2, 1000 cells; CHO-TAX 5-6, 1000 cells; CEM-VLB,
20000 cells)in appropriate medium. Plates were incubated at 37  C, 5%
CO2 for 24 h. Freshly solubilized drugs in DMSO were diluted in fresh
medium, and 75 μL aliquots containing increasing concentrations
(0.98 1000 nM) of the drug were added. Plates were incubated for 48 h.
Figure 5. Contour maps of CoMFA ﬁelds contributing to ligand
binding generated by PLS analysis in model G (HT-29). Compound
45 (ball-and-stick model) is shown as a reference to depict the ﬁeld
region. (A) Contour map of steric ﬁeld. Green areas present the favored
stericinteractionfromtheligands,andtheyellowareasshowtheregions
that disfavored steric contribution. (B) Contour map of electrostatic
ﬁeld. Blue areas depict favored electrostatic regions; increasing positive
charge will contribute to higher activity. Red areas show the disfavored
electrostatic areas, where higher ligand binding does not like higher
positive charge.4571 dx.doi.org/10.1021/jm200488a |J. Med. Chem. 2011, 54, 4559–4580
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Plates containing attached cell lines were then stained with sulforhoda-
mineB.Briefly,cellswerefixedbyadditionofcoldtrichloroaceticacidto
the wells (10% (w/v) final concentration), for 30 min at 4  C. Plates
were washed five times with tap water and dried. Sulforhodamine B
solution(50μL)at0.1%(w/v)in1%aceticacidwasaddedtoeachwell,
and plates were incubated for 15 min at room temperature. Unbound
dye was removed by washing five times with 1% acetic acid. Bonded dye
was solubilized in 10 mM Tris base, and the absorbance was read using
a μQuant Universal microplate spectrophotometer (Biotek, Winooski,
VT) at a wavelength between 530 and 565 nm according to color
intensity. For cells in suspension resazurin staining was used. Briefly,
supernatant was aspirated and an amount of 100 μL of resazurin at
25 μg/mL in fresh medium was added. Plates were incubated at 37  C
for 1 3 h according to cell line sensitivity. Fluorescence was read on a
FL-500fluorometer(Biotek,Winooski,VT)using530nmforexcitation
wavelengthand590nmforemissionwavelength.Theexperimentswere
performedatleasttwiceintriplicate.TheIC50assaywasconsideredvalid
when the relative standard deviation was less than 10%.
Cell Cycle Analysis. After incubation of 2.5   10
5 M21 cells with
the drugs at 2 and 5 times their respective IC50, for 24 h, the cells were
trypsinized, washed with phosphate buffered saline (PBS), resuspended
in250μLofPBS,fixedbytheadditionof750μLofice-coldethanol,and
stored at  20  C until use. Afterward, the cells were centrifuged for
5minat1000g.CellpelletswerewashedwithPBSandwereresuspended
in 450 μL of PBS containing 200 μg/mL RNase. After 5 min, 25 μLo f
PBS containing 1 mg/mL propidium iodide was added. Mixtures were
incubated on ice for 1 h, and then cell cycle distribution was analyzed
usinganEpicsEliteESPflowcytometer(CoulterCorporation,Miami,FL).
Inhibition of EBI-Binding to β-Tubulin. Six-well plates were
seeded with MDA-MB-231 cells at 7   10
5 cells per well and incubated
for24h.Cellswerefirstincubatedinthepresenceofapproximately1000
timestheIC50ofthedrugsfor2h,andafterwardtheyweretreatedbythe
addition of EBI (Toronto Research Chemicals, North York, Ontario,
Canada) (100μM,finalconcentration) for1.5hat37 Cwithoutchanging
the culture medium, which contains the drug tested. The control cells
were treated with 0.5% dimethylsulfoxide. Afterward, floating and adherent
cells were harvested using a rubber policeman and centrifuged for 3 min
at 8000 rpm. The pellets were washed with 500 μL of cold PBS and
stored at  80  C until use. The cells pellets were resuspended in PBS
and lysed by sonication. The protein concentration was determined
using the Bio-Rad protein assay (Bio-Rad Laboratories, Mississauga,
Canada).Samplesweredilutedat2mg/mLproteininLaemmlibuffer
62
(60mMTris-Cl,pH6.8,2%SDS,10%glycerol,5%β-mercaptoethanol,
0.01% bromophenol blue). Cell extracts were boiled for 5 min. An
amount of 20 μg of proteins from the protein extracts was subjected to
electrophoresis using 10% polyacrylamide gel. The proteins were
transferred onto nitrocellulose membranes that were incubated with
TBSMT (Tris-buffered saline þ 0.1% (v/v) Tween-20 with 2.5% fat-
free dry milk) for 1 h at room temperature and then with the anti-β-
tubulin (clone TUB 2.1) (Sigma-Aldrich, St. Louis, MO) primary
antibody in TBSMT (1:500) for 16 h at 4  C. Membranes were washed
withTBST(tris-bufferedsalineþ0.1%(v/v)Tween-20)andincubated
with peroxidase-conjugated antimouse immunoglobulin (Amersham
Canada (Oakville, Canada)) in TBSMT (1:2500) for 2.5 h at room
temperature. After the membranes were washed with TBST, detection
of the immunoblot was carried out with an enhanced chemilumines-
cence detection reagent kit provided by Amersham Canada (Oakville,
Canada).
FluorescenceMicroscopy.M21cellswereseededat1 10
5cells
per well in six-well plates that contained 22 μm glass coverslips coated
with fibronectin (10 μg/mL) and incubated for 24 h at 37  C. Tumor
cells were incubated either with most potent PIB-SOs, CA-4, and
compound 6 at 5 times their respective IC50 or with DMSO (0.5%)
for16 h.Afterward, the cellswere washed twicewith PBSand thenfixed
with 3.7% formaldehyde in PBS for 10 min. After two washes with PBS,
thecellswerepermeabilizedwith0.1%saponininPBSandblockedwith
3%(w/v)BSAinPBSfor1hat37 C.Thecellswerethenincubatedfor
2 h at room temperature with the anti-β-tubulin (clone TUB 2.1) in a
solutioncontaining0.1%saponinand3%BSAinPBS(1:200).Thecells
were washed five times with PBS containing 0.05% Tween-20 and
incubated for 1 h at 37  C in blocking buffer containing anti-mouse IgG
Alexa-488 (Molecular Probes, Eugene, OR) (1:1000) and 40,60-diami-
dino-2-phenylindole (2.5 μg/mL in PBS) to stain the cellular nuclei
(1:2000).Cellswerethenmountedonamicroscopeslideovernightwith
slow fade reagent (DakoCytomation, Carpinteria, CA) before analysis
under a Olympus BX51 microscope. Images were captured as 8-bit
tagged image format files with a Q imaging RETIGA EXI digital camera
driven by Image Pro Express software.
CAMTumorAssay.HumanHT-1080fibrosarcomacellswereused
to assess the antitumoral activity of PIB-SOs in the CAM assay.
58,59,63
Briefly, fertilized chicken eggs purchased from Couvoirs Victoriaville
(Victoriaville, Qu  ebec, Canada) were incubated for 10 days in a Pro-FI
egg incubator fitted with an automatic egg turner before being trans-
ferred to a Roll-X static incubator for the rest of the incubation time
(incubators werepurchasedfromLyonElectric,ChulaVista,SanDiego,
CA).Theeggswerekeptat37 Cina60%humidityatmosphereforthe
entire incubation period. On day 10, by use of a hobby drill (Dremel,
Racine, WI), a hole was drilled on the side of the egg and a negative
pressure was applied to create a new air sac. A window was opened on
this new air sac and was covered with transparent adhesive tape to pre-
vent contamination. A freshly prepared cell suspension (40 μL) of HT-
1080 (3.5   10
5 cells/egg) cells was applied directly onto the freshly
exposed CAM tissue through the window. On day 11, the drugs
dissolved in DMSO were extemporaneously diluted in the excipient
(cremophor/ethanol 99%/PBS, 6.25/6.25/87.5 v/v). The concentra-
tionofDMSOintheexcipientwaskeptbelow0.5%toavoiditspotential
toxicity. The drug dissolved in 100 μL of excipient was injected iv into
10 12 eggs. The eggs were incubated until day 17, at which time the
embryos were euthanized at 4  C followed by decapitation. Tumors
were collected, and the tumor-wet weights were recorded. The number
of dead embryos and signs of toxicity from the different groups were
recorded.
Chemical Procedures. General. Proton NMR spectra were
recorded ona BrukerAM-300 spectrometer(Bruker, Germany).Chemical
shifts(δ)arereportedinpartspermillion.IRspectrawererecordedona
MagnaFT-IRspectrometer(NicoletInstrumentCorporation,Madison,
WI, U.S.). Uncorrected melting points were determined on an Electro-
thermal melting point apparatus. HPLC analyses were performed on an
Acquity UPLC sample and binary solvent manager equipped with a
Quattro Premier XE tandem quadrupole mass spectrometer (Waters,
Milford, MA, U.S.). A Waters BECH C18 reversed-phase column (1.7 μm,
2.1 mm   50 mm, 50  C) was eluted in 7 min with a methanol/water
linear gradient containing 0.1% TFA at 0.6 mL/min. The purity of the
final compounds was greater than 95%. All reactions were conducted
under adriednitrogen atmosphere. Chemicals were supplied by Aldrich
Chemicals (Milwaukee, WI, U.S.) or VWR International (Mont-Royal,
Qu  ebec, Canada). Liquid flashchromatography was performed onsilica
gelF60,60A,40 63μmsuppliedbySilicycle(Qu  ebec,Canada)usinga
FPX flash purification system (Biotage, Charlottesville, VA, U.S.) and
using the indicated solvent mixture expressed as volume/volume ratios.
Solvents and reagents were used without purification unless specified
otherwise. The progress of all reactions was monitored using TLC on
precoated silica gel plates 60 F254 (VWR International, Mont-Royal,
Qu  ebec, Canada). The chromatograms were viewed under UV light at
254 and/or 265 nm.
General Preparation of Compounds 9 81. Method A. To a
stirred solution of the appropriate N-phenyl-N0-(2-chloroethyl)urea
derivative (0.4 mmol) in acetonitrile (10 mL) a mixture of aluminum4572 dx.doi.org/10.1021/jm200488a |J. Med. Chem. 2011, 54, 4559–4580
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oxide and potassium fluoride (6:4) (4.0 mmol) was added. The sus-
pension was refluxed overnight. After cooling, the mixture was filtered
and the solvent evaporated under reduced pressure. The residue was
purified by recrystallization or flash chromatography on silica gel.
Method B. 4-(2-Oxoimidazolidin-1-yl)benzene-1-sulfonyl chloride
or 4-(tetrahydro-2-oxopyrimidin-1(2H)-yl)benzene-1-sulfonyl chloride
(8.00 mmol) was suspended in dry methylene chloride (10 mL) under
nitrogen atmosphere. Appropriate phenol (8.00 mmol) and triethyla-
mine (8.00 mmol) were successively added dropwise, and the mixture
was stirred at room temperature for 24 h. The mixture was evaporated
and theresidue dissolved with ethylacetate (100 mL).Thesolution was
washed with hydrochloric acid 1 N (100 mL), sodium hydroxide 1 N
(100 mL), brine (100 mL), dried over sodium sulfate, filtered, and
evaporated to dryness under vacuum. The residue was purified by flash
chromatography on silica gel.
MethodC.Amixtureoftheappropriatenitrocompound39,50,or62
(1 equiv) dissolved in ethanol 99% (30 mL) was added dropwise Pd/C
10% (0.02 equiv). The nitro compound was reduced under hydrogen
atmosphere (38 psi) overnight. The catalyst was removed by filtration,
and the filtrate was evaporated to dryness. The residue was purified by
flash chromatography on silica gel to give compounds 40, 51, and 63.
2-Tolyl-4-(2-oxoimidazolidin-1-yl)benzenesulfonate (9). Me-
thod A: recrystallization from methylene chloride/hexanes 1:20). Yield:
88%. Method B: flash chromatography (methylene chloride to methylene
chloride/ethyl acetate 8:2). Yield: 95%. White solid. Mp: 166 167  C. IR
ν:3242,1715cm
 1.
1HNMR(DMSO-d6):δ7.84 7.69(m,4H,Ar),7.44
(s, 1H, NH), 7.31 7.20 (m, 3H, Ar), 7.00 6.96 (m, 1H, Ar), 3.96 3.91
(m, 2H, CH2), 3.49 3.44 (m, 2H, CH2), 2.04 (s, 3H, CH3).
13CN M R
(DMSO-d6):δ158.2, 147.9,146.2, 131.7, 131.0, 129.3, 127.3, 127.2,126.0,
122.0, 116.4, 44.3, 36.3, 15.9. HRMS (ESþ) m/z found 333.0889;
C16H16N2O4S( M
þ þ H) requires 333.0909.
3-Tolyl-4-(2-oxoimidazolidin-1-yl)benzenesulfonate (10).
Method A: flash chromatography (methylene chloride to methylene
chloride/ethyl acetate 8:2). Yield: 56%. Method B: flash chromatogra-
phy (methylene chloride to methylene chloride/ethyl acetate 8:10).
Yield: 97%. White solid. Mp: 168 169  C. IR ν: 3217, 1704 cm
 1.
1H
NMR (CDCl3): δ 7.78 7.68 (m, 4H, Ar), 7.16 7.10 (m, 1H, Ar),
7.04 7.02 (m, 1H, Ar), 6.88 (s, 1H, Ar), 6.73 6.70 (m, 1H, Ar), 5.40
(brs, 1H, NH), 4.00 3.95 (m, 2H, CH2), 3.67 3.61 (m, 2H, CH2),
2.29 (s, 3H, CH3).
13C NMR (CDCl3): δ 159.2, 149.6, 145.3, 140.0,
129.6, 129.2, 127.9, 127.6, 122.9, 119.1, 116.6, 44.8, 37.1, 21.2. HRMS
(ESþ) m/z found 333.0354; C16H16N2O4S( M
þ þ H) requires
333.0909.
4-Tolyl-4-(2-oxoimidazolidin-1-yl)benzenesulfonate (11).
Method A: recrystallization from methylene chloride/hexanes 1:20.
Yield: 81%. Method B: flash chromatography (methylene chloride to
methylene chloride/ethyl acetate 8:2). Yield: 97%. White solid. Mp:
192 193  C. IR ν: 3252, 1713 cm
 1.
1H NMR (DMSO-d6): δ 7.80 
7.70(m,4H,Ar),7.40(s,1H,NH),7.15(d,2H,J=8.3Hz,Ar),6.87(d,
2H,J=8.3Hz,Ar),3.93 3.87(m,2H,CH2),3.46 3.41(m,2H,CH2),
2.25 (s, 3H, CH3).
13C NMR (DMSO-d6): δ 163.4, 152.2, 151.3, 142.0,
135.5, 134.6, 130.5, 127.0, 121.5, 49.4, 41.5, 25.6. HRMS (ESþ) m/z
found 333.0380; C16H16N2O4S( M
þ þ H) requires 333.0909.
4-Methoxyphenyl-4-(2-oxoimidazolidin-1-yl)benzenesul-
fonate (12). Method A: flash chromatography (methylene chloride to
methylene chloride/ethyl acetate 8:2). Yield: 62%. Method B: flash
chromatography (methylene chloride to methylene chloride/ethyl acetate
8:2).Yield:75%.Whitesolid.Mp:178 179 C.IRν:3244,1709cm
 1.
1H NMR (CDCl3 and MeOD): δ 7.68 7.60 (m, 4H, Ar), 6.82 6.79
(m, 2H, Ar), 6.72 6.69 (m, 2H, Ar), 3.94 3.89 (m, 2H, CH2), 3.70 (s,
3H, CH3), 3.58 3.53 (m, 2H, CH2).
13C NMR (CDCl3 and MeOD):
δ159.1,158.2,145.3,143.0,129.6,127.3,123.3,116.6,114.5,55.5,44.8,
37.0. HRMS (ESþ) m/z found 349.0853; C16H16N2O5S( M
þ þ H)
requires 349.0858.
4-(Dimethylamino)phenyl-4-(2-oxoimidazolidin-1-yl)ben-
zenesulfonate (13). Method A: flash chromatography (methylene
chloride to methylene chloride/ethyl acetate 8:2). Yield: 53%. Method
B: flash chromatography (methylene chloride to methylene chloride/
ethyl acetate (8:2). Yield: 17%. White solid. Mp: 206 207  C. IR ν:
2805, 1711cm
 1.
1HNMR(CDCl3andMeOD):δ7.64 7.55 (m,4H,
Ar), 6.79 (d,2H, J=9.1 Hz,Ar),6.52 (d, 2H,J=9.1 Hz,Ar), 3.90 3.85
(m, 2H, CH2), 3.54 3.48 (m, 3H, CH2 and NH), 2.80 (s, 6H, 2  
CH3).
13C NMR (CDCl3 and MeOD): δ 158.9, 149.3, 145.0, 140.3,
129.7, 128.1, 122.9, 116.6, 112.6, 44.8, 40.6, 37.0. HRMS (ESþ) m/z
found 362.0071; C17H19N3O4S( M
þ þ H) requires 362.1175.
4-Hydroxyphenyl-4-(2-oxoimidazolidin-1-yl)benzenesulfo-
nate(14).MethodA:flashchromatography(methylenechloride/ethyl
acetate/methanol 8:2:0 to 75:20:5). Yield: 35%. To a stirred solution of
58 (1 equiv) in tetrahydrofuran (10 mL) was added tetrabutylammo-
nium fluoride 1 M in tetrahydrofuran (1.1 equiv). The mixture was
stirred overnight. Then hydrochloric acid was added, the appropriate
layer was extracted with 3  ethyl acetate, washed with brine, and dried
with sodium sulfate, and the solvent was evaporated under reduced
pressure to afford 14. Yield: 99%. White solid. Mp: 241 242  C. IR ν:
3440, 1686 cm
 1.
1H NMR (DMSO-d6): δ 9.67 (s, 1H, OH),
7.81 7.69 (m, 4H, Ar), 7.41 (s, 1H, NH), 6.80 6.67 (m, 4H, Ar),
3.94 3.89 (m, 2H, CH2), 3.48 3.42 (m, 2H, CH2).
13C NMR
(DMSO-d6): δ 158.2, 157.0, 146.0, 140.9, 129.4, 125.4, 123.0, 116.3,
116.0, 44.2, 36.3. HRMS (ESþ) m/z found 334.9951; C15H14N2O5S
(M
þ þ H) requires 335.0702.
Phenyl-4-(2-oxoimidazolidin-1-yl)benzenesulfonate (15).
Method B: flash chromatography (ethyl acetate to ethyl acetate/
methanol 95:5). Yield: 75%. White solid. Mp: 149 151  C. IR ν:
3262, 1713 cm
 1.
1H NMR (DMSO-d6): δ 7.82 7.73 (m, 4H, Ar),
7.41 7.29(m,4H,ArorNH),7.03(s,1H,ArorNH),7.01(s,1H,Aror
NH), 3.94 3.89 (m, 2H, CH2), 3.48 3.43 (m, 2H, CH2).
13C NMR
(DMSO-d6): δ 158.2, 149.2, 146.1, 130.0, 129.4, 127.4, 125.3, 122.1,
116.3, 44.2, 36.3. HRMS (ESþ) m/z found 319.0589; C15H14N2O4S
(M
þ þ H) requires 319.0753.
2-Ethylphenyl-4-(2-oxoimidazolidin-1-yl)benzenesulfonate
(16). Method B: flash chromatography (methylene chloride to methy-
lene chloride/ethyl acetate 8:2). Yield: 48%. White solid. Mp: 163 
164  C. IR ν: 3264, 1712 cm
 1.
1H NMR (CDCl3 and DMSO-d6):
δ 7.42 7.35 (m, 4H, Ar), 6.88 6.83 (m, 1H Ar), 6.75 6.73 (m, 1H,
Ar), 6.52 (brs, 1H, NH), 6.46 6.41 (m, 2H, Ar), 3.64 3.59 (m, 2H,
CH2), 3.28 3.23 (m, 2H, CH2), 2.25 (q, 2H, J = 7.6 Hz, CH2), 0.82 (t,
3H, J = 7.6 Hz, CH3).
13C NMR (CDCl3 and DMSO-d6): δ 158.9,
148.0, 145.3, 137.3, 129.8, 129.5, 128.6, 127.1, 126.8, 122.1, 116.7, 44.9,
37.1, 22.8, 14.1. HRMS (ESþ) m/z found 347.0495; C17H18N2O4S
(M
þ þ H) requires 347.1066.
2-Propylphenyl-4-(2-oxoimidazolidin-1-yl)benzenesulfo-
nate (17). Method B: flash chromatography (methylene chloride to
methylene chloride/ethyl acetate 8:2). Yield: 90%. White solid. Mp:
153 154  C. IR ν: 3235, 1714 cm
 1.
1H NMR (CDCl3 and DMSO-
d6): δ 7.38 7.35 (m, 4H, Ar), 6.83 6.72 (m, 3H, Ar), 6.63 6.61 (m,
1H,Ar),6.56(s,1H,NH),3.61 3.56(m,2H,CH2),3.24 3.19(m,2H,
CH2), 2.05 (t, 2H, J = 7.7 Hz, CH2), 1.20 1.07 (m, 2H, CH2), 0.50
(t, 3H, J = 7.3 Hz, CH3).
13C NMR (CDCl3 and DMSO-d6): δ 158.2,
147.6, 146.2, 135.1, 130.8, 129.2, 127.3, 127.2, 126.1, 121.8, 116.4, 44.3,
36.3, 31.2, 22.6, 13.8. HRMS (ESþ) m/z found 361.0658; C18H20N2O4S
(M
þ þ H) requires 361.1222.
2-Methoxyphenyl-4-(2-oxoimidazolidin-1-yl)benzenesulfo-
nate (18). Method B: flash chromatography (ethyl acetate to ethyl
acetate/methanol 95:5). Yield: 76%. White solid. Mp: 183 185  C. IR
ν: 3236, 1715 cm
 1.
1H NMR (DMSO-d6): δ 7.81 7.71 (m, 4H, Ar),
7.40 (s, 1H, NH), 7.29 7.24 (m, 1H, Ar), 7.08 7.05 (m, 2H, Ar),
6.96 6.91 (m, 1H, Ar), 3.95 3.90 (m, 2H, CH2), 3.55 (s, 3H, CH3),
3.49 3.44(m,2H,CH2).
13CNMR(DMSO-d6):δ158.3,151.5,146.0,4573 dx.doi.org/10.1021/jm200488a |J. Med. Chem. 2011, 54, 4559–4580
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137.7, 129.4, 128.4, 126.2, 123.4, 120.6, 116.0, 113.4, 55.6, 44.3, 36.3.
HRMS(ESþ)m/zfound349.0858;C16H16N2O5S(M
þþH)requires
348.9406.
2-Ethoxyphenyl-4-(2-oxoimidazolidin-1-yl)benzenesulfo-
nate (19). Method B: flash chromatography (ethyl acetate to ethyl
acetate/methanol 95:5). Yield: 64%. White solid. Mp: 169 171  C. IR
ν:3236, 2907, 1713cm
 1.
1HNMR (DMSO-d6):δ7.81 7.70 (m,4H,
Ar), 7.40 (brs, 1H, NH), 7.27 7.22 (m, 1H, Ar), 7.14 7.12 (m, 1H,
Ar),7.05 7.02(m,1H,Ar),6.96 6.91(m,1H,Ar),3.94 3.89(m,2H,
CH2),3.81(q,2H,J=7.0Hz,CH2),3.46(m,2H,CH2),1.16(t,3H,J=
7.0 Hz, CH3).
13C NMR (DMSO-d6): δ 158.2, 150.7, 146.0, 137.7,
129.3, 128.3, 126.3, 123.6, 120.4, 116.1, 114.1, 63.8, 44.3, 36.3, 14.3.
HRMS(ESþ)m/zfound362.9793;C17H18N2O5S(M
þþH)requires
363.1015.
2-Chlorophenyl-4-(2-oxoimidazolidin-1-yl)benzenesulfo-
nate (20). Method B: flash chromatography (ethyl acetate to ethyl
acetate/methanol 95:5). Yield: 86%. White solid. Mp: 167 169  C. IR
ν:3255, 2909, 1709cm
 1.
1HNMR (DMSO-d6):δ7.85 7.78 (m,4H,
Ar),7.58 7.54(m,1H,Ar),7.43 7.33(m,3H,ArandNH),7.27 7.24
(m, 1H, Ar), 3.96 3.91 (m, 2H, CH2), 3.49 3.43 (m, 2H, CH2).
13C
NMR (DMSO-d6): δ 158.2, 146.5, 145.0, 130.9, 129.6, 128.7, 126.5,
125.3, 123.9, 116.4, 44.3, 36.3. HRMS (ESþ) m/z found 353.0363;
C15H13ClN2O4S( M
þ þ H) requires 353.0159.
2-Fluorophenyl-4-(2-oxoimidazolidin-1-yl)benzenesulfo-
nate (21). Method B: flash chromatography (ethyl acetate to ethyl
acetate/methanol 95:5). Yield: 67%. White solid. Mp: 164 166  C. IR
ν:3217, 2905, 1698cm
 1.
1HNMR (DMSO-d6):δ7.85 7.76 (m,4H,
Ar), 7.45 (brs, 1H, NH), 7.38 7.33 (m, 2H, Ar), 7.26 7.14 (m, 2H,
Ar), 3.96 3.91 (m, 2H, CH2), 3.49 3.44 (m, 2H, CH2).
13C NMR
(DMSO-d6): δ 158.2, 146.5, 129.5, 129.1, 129.0, 125.4, 125.3, 124.9,
124.6, 117.5, 117.2, 116.4, 44.3, 36.3. HRMS (ESþ) m/z found
337.0649; C15H13FN2O4S( M
þ þ H) requires 337.0658.
2-Iodophenyl-4-(2-oxoimidazolidin-1-yl)benzenesulfonate
(22). Method B: flash chromatography (ethyl acetate to ethyl acetate/
methanol 95:5). Yield: 73%. White solid. Mp: 205 207  C. IR ν: 3226,
2913, 1703 cm
 1.
1H NMR (DMSO-d6 and CDCl3): δ 7.74 7.72 (m,
5H, Ar), 7.33 7.28 (m, 1H, Ar), 7.19 7.17 (m, 1H, Ar), 7.11 (brs, 1H,
NH),6.99 6.94(m, 1H,Ar),3.93 3.88 (m,2H,CH2),3.53 3.48(m,
2H, CH2).
13C NMR (DMSO-d6 and CDCl3): δ 158.2, 149.5, 146.1,
139.7, 129.4, 129.3, 128.2, 126.1, 122.3, 116.0, 90.3, 44.2, 36.4. HRMS
(ESþ) m/z found 444.9523; C15H13IN2O4S( M
þ þ H) requires
444.9719.
2-Nitrophenyl-4-(2-oxoimidazolidin-1-yl)benzenesulfonate
(23). Method B: flash chromatography (methylene chloride to methy-
lene chloride/ethyl acetate 0:1). Yield: 83%. White solid. Mp: 181 
182  C. IR ν: 3423, 3113, 1710 cm
 1.
1H NMR (CDCl3, MeOD and
DMSO-d6): δ 7.22 7.16 (m, 1H, Ar), 7.06 7.03 (m, 2H, Ar),
6.97 6.88 (m, 3H, Ar), 6.79 6.73 (m, 1H, Ar), 6.45 6.43 (m, 1H,
Ar), 3.24 3.19 (m, 2H, CH2), 8.82 2.77 (m, 2H, CH2).
13C NMR
(CDCl3, MeOD and DMSO-d6): δ 158.5, 146.7, 143.2, 141.1, 134.5,
129.5, 128.0, 125.8, 125.0, 124.9, 116.5, 44.5, 36.6. HRMS (ESþ) m/z
found 363.9450; C15H13N3O6S( M
þ þ H) requires 364.0603.
2,3-Dimethylphenyl-4-(2-oxoimidazolidin-1-yl)benzene-
sulfonate (24). Method B: flash chromatography (ethyl acetate to
ethyl acetate/methanol 95:5). Yield: 72%. White solid. Mp: 190 192  C.
IR ν: 3242, 3118, 1716 cm
 1.
1H NMR (DMSO-d6 and CDCl3):
δ 7.75 7.65 (m, 4H, Ar), 7.17 (brs, 1H, NH), 7.02 6.94 (m, 2H, Ar),
6.74 6.72 (m, 1H, Ar), 3.93 3.89 (m, 2H, CH2), 3.53 3.48 (m, 2H,
CH2), 2.19 (s, 3H, CH3), 1.93 (s, 3H, CH3).
13C NMR (DMSO-d6 and
CDCl3): δ 158.3, 147.8, 145.8, 138.6, 129.7, 128.9, 128.0, 126.6, 125.7,
119.3, 116.0, 44.2, 36.5, 19.7, 12.4. HRMS (ESþ) m/z found 347.1050;
C17H18N2O4S( M
þ þ H) requires 347.1066.
2,4-Dimethylphenyl-4-(2-oxoimidazolidin-1-yl)benzene-
sulfonate(25).MethodB:flashchromatography(methylenechloride
to methylene chloride/ethyl acetate 8:2). Yield: 98%. White solid. Mp:
203 204  C. IR ν: 3228, 1714 cm
 1.
1H NMR (DMSO-d6): δ 7.84 
7.74 (m, 4H, Ar), 7.44 (s, 1H, NH), 7.07 6.99 (m, 2H, Ar), 6.83 6.81
(m, 1H, Ar), 3.96 3.90 (m, 2H, CH2), 3.49 3.43 (m, 2H, CH2), 2.25
(s,3H,CH3),1.98(s,3H,CH3).
13CNMR(DMSO-d6):δ158.2,146.1,
145.7, 136.5, 132.1, 130.6, 129.3, 127.6, 126.0, 121.7, 116.4, 44.3, 36.3,
20.3, 15.8. HRMS(ESþ)m/zfound 347.0571; C17H18N2O4S(M
þ þ H)
requires 347.1066.
2,5-Dimethylphenyl-4-(2-oxoimidazolidin-1-yl)benzene-
sulfonate (26). Method B: flash chromatography (ethyl acetate to
ethyl acetate/methanol 95:5). Yield: 76%. White solid. Mp: 184 186  C.
IR ν: 3241, 1710 cm
 1.
1H NMR (DMSO-d6): δ 7.84 7.76 (m, 4H,
Ar), 7.41 (brs, 1H, NH), 7.15 7.13 (m, 1H, Ar), 7.05 7.02 (m, 1H,
Ar), 6.86 (s, 1H, Ar), 3.95 3.90 (m, 2H, CH2), 3.49 3.43 (m, 2H,
CH2), 2.24 (s, 3H, CH3), 1.94 (s, 3H, CH3).
13C NMR (DMSO-d6):
δ 158.2, 147.6, 146.2, 136.8, 131.3, 129.2, 127.8, 127.6, 126.1, 122.5,
116.4, 44.3, 36.3, 20.4, 15.4. HRMS (ESþ) m/z found 347.1051;
C17H18N2O4S( M
þ þ H) requires 347.1066.
2,4,5-Trimethylphenyl-4-(2-oxoimidazolidin-1-yl)benzene-
sulfonate (27). Method B: flash chromatography (ethyl acetate to
ethyl acetate/methanol 95:5). Yield: 69%. White solid. Mp: 204 205  C.
IR ν: 3232, 2917, 1710 cm
 1.
1H NMR (DMSO-d6 and CDCl3):
δ 7.74 7.64 (m, 4H, Ar), 7.16 (brs, 1H, NH), 6.86 (s, 1H, Ar), 6.71 (s,
1H, Ar), 3.93 3.88 (m, 2H, CH2), 3.53 3.48 (m, 2H, CH2), 2.13 (s,
3H, CH3), 2.11 (s, 3H, CH3), 1.88 (s, 3H, CH3).
13C NMR (DMSO-d6
and CDCl3): δ 158.3, 145.7, 145.6, 134.8, 134.8, 132.1, 128.9, 127.5,
126.8,122.7,116.0,44.2,36.5,19.0,18.7,15.3.HRMS(ESþ)m/zfound
361.1190; C18H20N2O4S( M
þ þ H) requires 361.1222.
2,4,5-Trichlorophenyl-4-(2-oxoimidazolidin-1-yl)benzene-
sulfonate(28).MethodB:flashchromatography(methylenechloride
to methylene chloride/ethyl acetate 8:2). Yield: 62%. White solid. Mp:
186 187  C. IR ν: 3204, 1710 cm
 1.
1H NMR (DMSO-d6): δ 8.03 (s,
1H, Ar), 7.84 7.83 (m, 4H, Ar), 7.60 (s, 1H, Ar), 7.47 (brs, 1H, NH),
3.96 3.91 (m, 2H, CH2), 3.49 3.44 (m, 2H, CH2).
13C NMR
(DMSO-d6): δ 158.1, 146.9, 144.0, 131.7, 130.9, 130.7, 129.8, 126.6,
125.7, 124.5, 116.5, 44.3, 36.3. HRMS (ESþ) m/z found 420.8198;
C15H11Cl3N2O4S( M
þ þ H) requires 420.9583.
2,4,6-Trichlorophenyl-4-(2-oxoimidazolidin-1-yl)benzene-
sulfonate(29).MethodB:flashchromatography(methylenechloride
to methylene chloride/ethyl acetate 7:3). Yield: 75%. White solid. Mp:
254 255  C. IR ν: 3202, 1711 cm
 1.
1H NMR (CDCl3 þ MeOD):
δ 7.92 (d, 2H, J = 9.0 Hz, Ar), 7.73 (d, 2H, J = 9.0 Hz, Ar), 7.33 (s, 2H,
Ar), 4.01 3.96 (m, 2H, CH2), 3.64 3.59 (m, 2H, CH2).
13C NMR
(CDCl3þMeOD):δ159.9,149.8,145.7,137.7,130.9,129.8,129.1,119.6,
116.7, 44.8, 36.9. HRMS (ESþ) m/z found 420.9216; C15H11Cl3N2O4S
(M
þ þ H) requires 420.9583.
2,4-Difluorophenyl-4-(2-oxoimidazolidin-1-yl)benzenesul-
fonate (30). Method B: flash chromatography (ethyl acetate to ethyl
acetate/methanol 95:5). Yield: 85%. White solid. Mp: 179 183  C. IR
ν: 3236, 1722 cm
 1.
1H NMR (DMSO-d6 and CDCl3): δ 7.73 7.64
(m, 4H, Ar), 7.09 6.80 (m, 3H, Ar), 5.06 (br s, 1H, NH), 3.93 3.88
(m, 2H, CH2), 3.54 3.49 (m, 2H, CH2).
13C NMR (DMSO-d6 and
CDCl3): δ 158.2, 146.1, 129.1, 126.3, 125.2, 125.0, 116.0, 115.8, 111.4,
111.4,111.1,111.1,105.5, 105.2,105.1,104.8, 44.2,36.4.HRMS(ESþ)
m/z found 355.0443; C15H12F2N2O4S( M
þ þ H) requires 355.0564.
2,6-Difluorophenyl-4-(2-oxoimidazolidin-1-yl)benzenesul-
fonate (31). Method B: flash chromatography (ethyl acetate to ethyl
acetate/methanol 95:5). Yield: 81%. White solid. Mp: 187 189  C. IR
ν: 3240, 1732 cm
 1.
1H NMR (DMSO-d6 and CDCl3): δ 7.75 (s, 4H,
Ar), 7.27 7.17 (m, 2H, Ar or NH), 7.00 6.95 (m, 2H, Ar or NH),
3.95 3.90(m,2H,CH2),3.54 3.49(m,2H,CH2).
13CNMR(DMSO-
d6 and CDCl3): δ 158.2, 157.2, 157.1, 153.8, 153.8, 146.2, 129.1, 127.8,
127.7,127.6,125.7,125.6,116.1,112.4,112.4,112.4,112.2,112.2, 112.1,4574 dx.doi.org/10.1021/jm200488a |J. Med. Chem. 2011, 54, 4559–4580
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44.2, 36.4. HRMS (ESþ) m/z found 355.0549; C15H12F2N2O4S( M
þ þ
H) requires 355.0564.
Perfluorophenyl-4-(2-oxoimidazolidin-1-yl)benzenesulfo-
nate (32). Method B: flash chromatography (methylene chloride to
methylene chloride/ethyl acetate 8:2). Yield: 75%. White solid. Mp:
217 218  C. IR ν: 3258, 1711 cm
 1.
1H NMR (DMSO-d6): δ 7.93 
7.86 (m, 4H, Ar), 7.51 (brs, 1H, NH), 3.99 3.94 (m, 2H, CH2),
3.50 3.45 (m, 2H, CH2).
13C NMR (CDCl3 and MeOD): δ 164.2,
146.4, 146.3, 129.8, 116.9, 116.8, 44.8, 36.8. HRMS (ESþ) m/z found
409.0188; C15H9F5N2O4S( M
þ þ H) requires 409.0282.
3-Propylphenyl-4-(2-oxoimidazolidin-1-yl)benzenesulfo-
nate (33). Method B: flash chromatography (ethyl acetate to ethyl
acetate/methanol 95:5). Yield: 80%. White solid. Mp: 144 145  C. IR
ν: 3257, 2951, 1714 cm
 1.
1H NMR (DMSO-d6 and CDCl3): δ 7.72 
7.60 (m, 4H, Ar), 7.18 7.12 (m, 2H, Ar and NH), 7.02 7.00 (m, 1H,
Hz, Ar), 6.73 6.68 (m, 2H, Ar), 3.91 3.86 (m, 2H, CH2), 3.52 3.47
(m,2H,CH2),2.46(t,2H,J=7.7Hz,CH2),1.47(m,2H,CH2),0.79(t,
3H, J = 7.3 Hz, CH3).
13C NMR (DMSO-d6 and CDCl3): δ 158.2,
149.1, 145.7, 144.2, 129.0, 126.9, 125.9, 121.8, 119.1, 116.0, 44.2, 36.9,
36.4, 23.7, 13.2. HRMS (ESþ) m/z found 361.1315; C18H20N2O4S
(M
þ þ H) requires 361.1222.
3-Methoxyphenyl-4-(2-oxoimidazolidin-1-yl)benzenesul-
fonate (34). Method B: flash chromatography (methylene chloride to
methylene chloride/ethyl acetate 8:2). Yield: 70%. White solid. Mp:
139 140  C. IR ν: 3219, 1712 cm
 1.
1H NMR (CDCl3 and MeOD):
δ 7.73 7.62 (m, 4H, Ar), 7.13 7.08 (m, 1H, Ar), 6.74 6.71 (m, 1H,
Ar), 6.54 6.47 (m, 2H, Ar), 3.93 3.89 (m, 2H, CH2), 3.68 (s, 3H,
CH3), 3.59 3.54 (m, 2H, CH2), 2.60 (s, 1H, NH).
13C NMR (CDCl3
and MeOD): δ 160.4, 159.1, 150.5, 145.4, 129.9, 129.6, 127.5, 116.6,
114.3,113.0,108.3,55.5,44.8,36.9.HRMS(ESþ)m/zfound348.9994;
C16H16N2O5S( M
þ þ H) requires 349.0858.
3-Ethoxyphenyl-4-(2-oxoimidazolidin-1-yl)benzenesulfo-
nate (35). Method B: flash chromatography (ethyl acetate to ethyl
acetate/methanol 95:5). Yield: 81%. White solid. Mp: 143 145  C. IR
ν: 3255, 2898, 1713 cm
 1.
1H NMR (DMSO-d6 and CDCl3): δ
7.79 7.63 (m, 4H, Ar), 7.16 7.09 (m, 2H, Ar and NH), 6.75 6.71
(m, 1H, Ar), 6.47 6.42 (m, 2H, Ar), 3.92 3.86 (m, 4H, 2   CH2),
3.53 3.47 (m, 2H, CH2), 1.30 (t, 3H, J = 6.9 Hz, CH3).
13C NMR
(DMSO-d6 and CDCl3): δ 159.3, 158.2, 150.0, 145.8, 129.6, 129.0,
125.9, 116.0, 113.6, 113.0, 108.4, 63.3, 44.2, 36.5, 14.3. HRMS (ESþ)
m/z found 363.1002; C17H18N2O5S( M
þ þ H) requires 363.1015.
3-Chlorophenyl-4-(2-oxoimidazolidin-1-yl)benzenesulfo-
nate (36). Method B: flash chromatography (ethyl acetate to ethyl
acetate/methanol 95:5). Yield: 77%. White solid. Mp: 160 162  C. IR
ν: 3223, 1707 cm
 1.
1H NMR (DMSO-d6): δ 7.85 7.77 (m, 4H, Ar),
7.46 7.42 (m, 3H, Ar), 7.20 (s, 1H, NH), 7.02 6.98 (m, 1H, Ar),
3.96 3.90 (m, 2H, CH2), 3.49 3.44 (m, 2H, CH2).
13C NMR
(DMSO-d6): δ 158.2, 149.6, 146.4, 133.7, 131.4, 129.5, 127.6, 124.7,
122.5, 121.0, 116.4, 44.2, 36.3. HRMS (ESþ) m/z found 353.0349;
C15H13ClN2O4S( M
þ þ H) requires 353.0363.
3-Fluorophenyl-4-(2-oxoimidazolidin-1-yl)benzenesulfo-
nate (37). Method B: flash chromatography (methylene chloride to
methylene chloride/ethyl acetate 8:2). Yield: 56%. White solid. Mp:
157 158  C. IR ν: 3243, 1712 cm
 1.
1H NMR (CDCl3 and MeOD):
δ 7.68 7.58 (m, 4H, Ar), 7.21 7.13 (m, 1H, Ar), 6.91 6.85 (m, 1H,
Ar), 6.71 6.66 (m, 2H, Ar), 3.91 3.86 (m, 2H, CH2), 3.54 3.53 (m,
2H,CH2).
13CNMR(CDCl3andMeOD):δ160.9,159.1,150.1,145.6,
130.4,129.5,126.9,118.1,116.7,114.2,110.4,44.8, 36.9.HRMS(ESþ)
m/z found 337.0745; C15H13FN2O4S( M
þ þ H) requires 337.0658.
3-Iodophenyl-4-(2-oxoimidazolidin-1-yl)benzenesulfonate
(38). Method B: flash chromatography (ethyl acetate to ethyl acetate/
methanol 95:5). Yield: 80%. White solid. Mp: 182 184  C. IR ν: 3250,
2906, 1711 cm
 1.
1H NMR (DMSO-d6 and CDCl3): δ 7.76 7.64 (m,
4H,Ar),7.57(d,1H,J=8.0Hz,Ar),7.34 7.32(m,1H,Ar),7.25(s,1H,
NH),7.04(t,1H,J=8.0Hz,Ar),6.90 6.86(m,1H,Ar),3.93 3.88(m,
2H, CH2), 3.52 3.47 (m, 2H, CH2).
13C NMR (DMSO-d6 and
CDCl3): δ 158.2, 149.3, 146.1, 135.8, 131.0, 129.1, 125.2, 121.4,
116.1, 93.5, 44.2, 36.4. HRMS (ESþ) m/z found 444.9700; C15H13I-
N2O4S( M
þ þ H) requires 444.9719.
3-Nitrophenyl-4-(2-oxoimidazolidin-1-yl)benzenesulfonate
(39). Method B: flash chromatography (methylene chloride to methy-
lenechloride/ethylacetate8:2).Yield:98%.Whitesolid.Mp:152 153 C.
IR ν: 3248, 1713 cm
 1.
1H NMR (CDCl3): δ 8.10 7.66 (m, 6H, Ar),
7.50 7.45 (m, 1H, Ar), 7.35 7.32 (m, 1H, Ar), 3.97 3.92 (m, 2H,
CH2), 3.63 3.57 (m, 2H, CH2).
13C NMR (CDCl3): δ 159.0, 149.7,
146.0, 130.5, 129.7, 128.9, 128.4, 126.3, 122.0, 118.0, 116.8, 44.8, 36.9.
HRMS(ESþ)m/zfound364.0343;C15H13N3O6S(M
þþH)requires
364.0603.
3-Aminophenyl-4-(2-oxoimidazolidin-1-yl)benzenesulfo-
nate (40). Method C: flash chromatography (methylene chloride to
methylene chloride/methanol 9:1). Yield: 32%. White solid. Mp:
184 185  C. IR ν: 3233, 1709 cm
 1.
1H NMR (acetone-d6): δ 7.87 
7.73 (m, 4H, Ar), 6.96 (t, 1H, J = 8.1 Hz, Ar), 6.56 6.53 (m, 1H, Ar),
6.41 6.40 (m, 1H, Ar), 6.18 6.15 (m, 1H, Ar), 4.92 (s, 1H, NH),
4.04 4.00 (m, 2H, CH2), 3.64 3.59 (m, 2H, CH2).
13C NMR
(acetone-d6): δ 159.2, 150.8, 147.0, 130.4, 130.2, 130.0, 117.0, 117.0,
113.5, 110.2, 108.4, 45.3, 37.4. HRMS (ESþ) m/z found 334.0578;
C15H15N3O4S( M
þ þ H) requires 334.0862.
3,5-Dimethylphenyl-4-(2-oxoimidazolidin-1-yl)benzenesul-
fonate (41). Method B: flash chromatography (ethyl acetate to ethyl
acetate/methanol 95:5). Yield: 75%. White solid. Mp: 200 203  C. IR
ν: 3230, 1711 cm
 1.
1H NMR (DMSO-d6): δ 7.83 7.75 (m, 4H, Ar),
7.41 (s, 1H, Ar or NH), 6.95 (s, 1H, Aror NH), 6.65 (s, 2H, Ar or NH),
3.95 3.89 (m, 2H, CH2), 3.48 3.43 (m, 2H, CH2), 2.21 (s, 6H, 2  
CH3).
13CNMR(DMSO-d6):δ158.2,149.1,146.1,139.4,129.3,128.7,
125.6,119.4,116.3,44.3,36.3,20.7.HRMS(ESþ)m/zfound347.0825;
C17H18N2O4S( M
þ þ H) requires 347.1066.
3,4,5-Trimethylphenyl-4-(2-oxoimidazolidin-1-yl)benzene-
sulfonate(42).MethodB:flashchromatography(methylenechloride
to methylene chloride/ethyl acetate 0:1 to ethyl acetate/methanol
95:5). Yield: 79%. White solid. Mp: 211 212  C. IR ν: 3223, 2910,
1713 cm
 1.
1H NMR (DMSO-d6): δ 7.83 7.75 (m, 4H, Ar), 7.42 (s,
1H,NH),6.67(s,2H,Ar),3.95 3.90(m,2H,CH2),3.49 3.44(m,2H,
CH2), 2.17 (s, 6H, 2   CH3), 2.07 (s, 3H, CH3).
13C NMR (DMSO-
d6): δ 158.3, 146.4, 146.0, 137.8, 134.0, 129.3, 125.8, 120.4, 116.3, 44.3,
36.3, 20.2, 14.7. HRMS (ESþ) m/z found 361.1224; C18H20N2O4S
(M
þ þ H) requires 361.1222.
3,4-Dimethoxyphenyl-4-(2-oxoimidazolidin-1-yl)benzene-
sulfonate(43).MethodB:flashchromatography(methylenechloride
to methylene chloride/ethyl acetate 0:1). Yield: 70%. White solid. Mp:
156 158  C. IR ν: 3235, 2969, 1710 cm
 1.
1H NMR (CDCl3 and
MeOD): δ 7.66 7.58 (m, 4H, Ar), 6.63 6.60 (m, 1H, Ar), 6.48 6.47
(m, 1H, Ar), 6.38 6.34 (m, 1H, Ar), 3.90 3.85 (m, 2H, CH2), 3.73 (s,
3H, CH3), 3.66 (s, 3H, CH3), 3.54 3.50 (m, 2H, CH2), 3.32 (s, 1H,
NH).
13C NMR (CDCl3 and MeOD): δ 159.1, 149.2, 147.8, 145.4,
143.1, 129.6, 127.2, 116.6, 113.8, 110.9, 106.5, 56.0, 56.0, 44.8, 36.9.
HRMS(ESþ)m/zfound378.9391;C17H18N2O6S(M
þþH)requires
379.0964.
3,5-Dimethoxyphenyl-4-(2-oxoimidazolidin-1-yl)benzene-
sulfonate (44). Method B: flash chromatography (ethyl acetate to
ethyl acetate/methanol 95:5). Yield: 71%. White solid. Mp: 219 221  C.
IR ν: 3235, 1711 cm
 1.
1H NMR (DMSO-d6): δ 7.85 7.78 (m, 4H,
Ar), 7.43 (s, 1H, NH), 6.46 6.45 (m, 1H, Ar), 6.18 6.17 (m, 2H, Ar),
3.95 3.90(m,2H,CH2),3.68(s,6H,2 CH3),3.49 3.44(m,2H,CH2).
13CNMR(DMSO-d6):δ160.8,158.2,150.6,146.2,129.5,125.3,116.4,
100.6, 99.0, 55.6, 44.3, 36.3. HRMS (ESþ) m/z found 379.0945;
C17H18N2O6S( M
þ þ H) requires 379.0964.4575 dx.doi.org/10.1021/jm200488a |J. Med. Chem. 2011, 54, 4559–4580
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3,4,5-Trimethoxyphenyl-4-(2-oxoimidazolidin-1-yl)benzene-
sulfonate(45).MethodB:flashchromatography(methylenechloride
tomethylenechloride/ethyl acetate7:3).Yield:31%.Mp:191 192 C.
IR ν: 3201, 1706 cm
 1.
1H NMR (DMSO-d6): δ 7.86 7.80 (m, 4H,
Ar), 7.42 (s, 1H, NH), 6.31 (s, 2H, Ar), 3.95 3.90 (m, 2H, CH2), 3.65
(s, 6H, 2   CH3), 3.63 (s, 3H, CH3), 3.49 3.44 (m, 2H, CH2).
13C
NMR (DMSO-d6): δ 158.2, 153.1, 146.2, 145.1, 136.3, 129.6, 125.2,
116.4, 100.0, 60.1, 56.1, 44.3, 36.2. HRMS (ESþ) m/z found 409.1068;
C18H20N2O7S( M
þ þ H) requires 409.1070.
3,5-Dichlorophenyl-4-(2-oxoimidazolidin-1-yl)benzenesul-
fonate (46). Method B: flash chromatography (ethyl acetate to ethyl
acetate/methanol 95:5). Yield: 64%. White solid. Mp: 179 181  C. IR
ν: 3236, 1709 cm
 1.
1H NMR (DMSO-d6): δ 7.87 7.80 (m, 4H, Ar),
7.66 (m, 1H, Ar), 7.46 (s, 1H, NH), 7.21 7.20 (m, 2H, Ar), 3.97 3.91
(m, 2H, CH2), 3.49 3.44 (m, 2H, CH2).
13C NMR (DMSO-d6):
δ158.2,149.7,146.6,134.7,129.6,127.6,124.3,121.7,116.4,44.2,36.3.
HRMS (ESþ) m/z found 386.9956; C15H12Cl2N2O4S( M
þ þ H)
requires 386.9973.
3,4-Difluorophenyl-4-(2-oxoimidazolidin-1-yl)benzenesul-
fonate (47). Method B: flash chromatography (ethyl acetate to ethyl
acetate/methanol 95:5). Yield: 78%. White solid. Mp: 182 184  C. IR
ν: 3230, 2918, 1716 cm
 1.
1H NMR (DMSO-d6 and CDCl3): δ
7.77 7.51 (m, 5H, Ar and NH), 7.27 7.18 (m, 1H, Ar), 7.03 6.96
(m, 1H, Ar), 6.77 6.72 (m, 1H, Ar), 3.93 3.83 (m, 2H, CH2),
3.51 3.43 (m, 2H, CH2).
13C NMR (DMSO-d6 and CDCl3): δ 158.8,
158.1,146.2,141.6,138.9,129.2,126.2,124.8,118.8,118.8,118.7,118.7,
117.7, 117.5, 116.2, 115.8, 112.4, 112.1, 44.5, 44.2, 36.6, 36.4. HRMS
(ESþ) m/z found 354.9966; C15H12F2N2O4S( M
þ þ H) requires
355.0564.
3,5-Difluorophenyl-4-(2-oxoimidazolidin-1-yl)benzenesul-
fonate (48). Method B: flash chromatography (ethyl acetate to ethyl
acetate/methanol 95:5). Yield: 90%. White solid. Mp: 172 174  C. IR
ν: 3225, 1716 cm
 1.
1H NMR (DMSO-d6 and CDCl3): δ 7.75 7.66
(m, 4H, Ar), 7.07 (s, 1H, NH), 6.81 6.74 (m, 1H, Ar), 6.59 6.55 (m,
2H,Ar),3.93 3.87(m,2H,CH2),3.54 3.48(m,2H,CH2).
13CNMR
(DMSO-d6 and CDCl3): δ 164.0, 163.8, 160.7, 160.5, 158.2, 150.2,
146.1,129.1,125.0,116.1,106.4,106.3,106.1,106.0,103.0,102.7,102.3,
44.2, 36.4. HRMS (ESþ) m/z found 355.0141; C15H12F2N2O4S( M
þ
þ H) requires 355.0564.
3,4,5-Trifluorophenyl-4-(2-oxoimidazolidin-1-yl)benzene-
sulfonate (49). Method B: flash chromatography (ethyl acetate to
ethyl acetate/methanol 95:5). Yield: 99%. White solid. Mp: 178 180  C.
IR ν: 3238, 2914, 1714 cm
 1.
1HN M R(D M S O - d6and CDCl3):δ7.78 
7.67 (m, 4H, Ar), 7.24 (s, 1H, NH), 6.84 6.77 (m, 2H, Ar), 3.94 3.89
(m, 2H, CH2), 3.53 3.48 (m, 2H, CH2).
13C NMR (DMSO-d6 and
CDCl3): δ 158.1, 152.0, 151.9, 151.9, 151.8, 148.7, 148.6, 148.5, 148.5,
146.4,143.8,143.8,143.7,140.3,140.1,139.9,136.8,129.2,124.5,116.2,
108.0, 107.9, 107.8, 107.7, 44.2, 36.4. HRMS (ESþ) m/z found
372.9821; C15H11F3N2O4S( M
þ þ H) requires 373.0470.
3-Methyl-4-nitrophenyl-4-(2-oxoimidazolidin-1-yl)benzene-
sulfonate(50).MethodB:flashchromatography(methylenechloride
to methylene chloride/ethyl acetate 8:2). Yield: 65%. White solid. Mp:
215 216  C. IR ν: 3225, 1713 cm
 1.
1H NMR (DMSO-d6): δ 8.03 (d,
1H, J = 8.9 Hz, Ar), 7.85 7.81 (m, 4H, Ar), 7.45 (s, 1H, NH),
7.32 7.31 (m, 1H, Ar), 7.10 7.07 (m, 1H, Ar), 3.95 3.90 (m, 2H,
CH2),3.48 3.43(m,2H,CH2),2.49(s,3H,CH3).
13CNMR(DMSO-
d6):δ158.2,151.5,147.3,146.5,135.7,129.5,126.7,126.0,124.7,120.6,
116.5, 44.2, 36.3, 19.5. HRMS (ESþ) m/zfound 378.0916; C16H15N3O6S
(M
þ þ H) requires 378.0760.
4-Amino-3-methylphenyl-4-(2-oxoimidazolidin-1-yl)ben-
zenesulfonate (51). Method C: flash chromatography (methylene
chloride to methylene chloride/methanol 9:1). Yield: 31%.yellow solid.
Mp: 160 162  C. IR ν: 3228, 1709 cm
 1.
1H NMR (acetone-d6):
δ 7.87 7.70 (m, 4H, Ar), 6.75 6.69 (m, 1H, Ar), 6.57 6.37 (m, 2H,
Ar), 4.55 (s, 1H, NH), 4.06 4.00 (m, 2H, CH2), 3.65 3.59 (m, 2H,
CH2),1.29(s,3H,CH3).
13CNMR(acetone-d6):δ159.1,146.9,146.0,
141.4, 130.1, 124.6, 124.5, 120.9, 120.7, 116.9, 114.8, 45.3, 37.4, 17.4.
HRMS(ESþ)m/zfound348.1060;C16H17N3O4S(M
þþH)requires
348.1018.
4-Ethylphenyl-4-(2-oxoimidazolidin-1-yl)benzenesulfonate
(52). Method B: flash chromatography (ethyl acetate to ethyl acetate/
methanol 95:5). Yield: 79%. White solid. Mp: 155 157  C. IR ν: 3230,
1715 cm
 1.
1H NMR (DMSO-d6): δ 7.83 7.74 (m, 4H, Ar), 7.42 (s,
1H, NH), 7.21 (d, 2H, J = 8.4 Hz, Ar), 6.92 (d, 2H, J = 8.4 Hz, Ar),
3.95 3.90(m,2H,CH2),3.49 3.43(m,2H,CH2),2.58(q,2H,J=7.5
Hz, CH2), 1.15 (t, 3H, J = 7.5 Hz, CH3).
13C NMR (DMSO-d6):
δ158.2,147.2,146.1,142.9,129.4,129.2,125.4,121.9,116.3,44.2,36.3,
27.5, 15.4. HRMS (ESþ) m/z found 347.0906; C17H18N2O4S( M
þ þ
H) requires 347.1066.
4-Propylphenyl-4-(2-oxoimidazolidin-1-yl)benzenesulfo-
nate (53). Method B: flash chromatography (ethyl acetate to ethyl
acetate/methanol 95:5). Yield: 78%. White solid. Mp: 198 200  C. IR
ν:3208,2955,1712cm
 1.
1HNMR(DMSO-d6andCDCl3):δ7.68 7.60
(m, 4H,Ar),7.02 (s,1H,Aror NH),6.99(s,1H,ArorNH),6.79 6.76
(m, 3H, Ar), 3.91 3.86 (m, 2H, CH2), 3.54 3.49 (m, 2H, CH2), 2.47
(t, 2H, J = 7.6 Hz, CH2), 1.59 1.47 (m, 2H, CH2), 0.84 (t, 3H, J = 7.3
Hz, CH3).
13C NMR (DMSO-d6 and CDCl3): δ 158.3, 147.1, 145.4,
141.2, 129.0, 129.0, 126.3, 121.5, 116.0, 44.2, 36.8, 36.5, 23.8, 13.3.
HRMS(ESþ)m/zfound361.0652;C18H20N2O4S(M
þþH)requires
361.1222.
4-sec-Butylphenyl-4-(2-oxoimidazolidin-1-yl)benzenesul-
fonate (54). Method B: flash chromatography (methylene chloride to
methylene chloride/ethyl acetate 8:2). Yield: 74%. White solid. Mp:
179 180  C. IR ν: 3245, 1711 cm
 1.
1H NMR (acetone-d6): δ 7.90 
7.73 (m, 4H, Ar), 7.19 (d, 2H, J = 8.6 Hz, Ar), 6.95 (d, 2H, J = 8.6 Hz,
Ar), 6.40 (brs, 1H, NH), 4.06 4.01 (m, 2H, CH2), 3.65 3.60 (m, 2H,
CH2), 2.65 2.58 (m, 1H, CH), 1.58 1.23 (m, 2H, CH2), 1.18 (d, 3H,
J=6.9Hz,CH3),0.77(t,3H,J=7.4Hz,CH3).
13CNMR(acetone-d6):
δ 159.0, 147.6, 146.6, 145.3, 129.7, 128.1, 127.9, 122.1, 116.6, 44.9,
41.1, 37.1, 31.1, 21.7, 12.1. HRMS (ESþ) m/z found 375.0776;
C19H22N2O4S( M
þ þ H) requires 375.1379.
4-Ethoxyphenyl-4-(2-oxoimidazolidin-1-yl)benzenesulfo-
nate (55). Method B: flash chromatography (ethyl acetate to ethyl
acetate/methanol 95:5). Yield: 76%. White solid. Mp: 185 187  C. IR
ν: 3236, 2908, 1710 cm
 1.
1H NMR (DMSO-d6 and CDCl3): δ 7.70 
7.58 (m, 4H, Ar), 7.01 (s, 1H, NH), 6.79 6.75 (m, 2H, Ar), 6.72 6.68
(m, 2H, Ar), 3.95 3.86 (m, 4H, 2   CH2), 3.53 3.48 (m, 2H, CH2),
1.32 (t, 3H, J = 7.0 Hz, CH3).
13C NMR (DMSO-d6 and CDCl3):
δ158.3,157.1,145.6,142.4,129.0,125.9,122.9,115.9,114.6,63.3,44.2,
36.5, 14.4. HRMS (ESþ) m/z found 363.0692; C17H18N2O5S( M
þ þ
H) requires 363.1015.
4-Propoxyphenyl-4-(2-oxoimidazolidin-1-yl)benzenesul-
fonate (56). Method B: flash chromatography (methylene chloride to
methylene chloride/ethyl acetate 8:2). Yield: 56%. White solid. Mp:
156 157  C. IR ν: 3226, 1711 cm
 1.
1H NMR (CDCl3): δ 7.74 7.65
(m, 4H, Ar), 6.87 6.83 (m, 2H, Ar), 6.76 6.72 (m, 2H, Ar), 5.73 (s,
1H, NH), 3.98 3.93 (m, 2H, CH2), 3.84 (t, 2H, J = 6.5 Hz, CH2),
3.66 3.60 (m, 2H, CH2), 1.80 1.71 (m, 2H, CH2), 1.00 (t, 3H, J =7.4
Hz, CH3).
13C NMR (CDCl3): δ 158.9, 157.8, 145.3, 142.9, 129.7,
127.6, 123.3, 116.6, 115.0, 69.9, 44.9, 37.1, 22.5, 10.5. HRMS (ESþ) m/z
found 377.0320; C18H20N2O5S( M
þ þ H) requires 377.1171.
4-Butoxyphenyl-4-(2-oxoimidazolidin-1-yl)benzenesulfo-
nate (57). Method B: flash chromatography (methylene chloride to
methylene chloride/ethyl acetate 8:2). Yield: 58%. White solid. Mp:
151 152  C. IR ν: 3218, 1696 cm
 1.
1H NMR (CDCl3): δ 7.67 7.59
(m,4H,Ar),6.80 6.76(m,2H,Ar),6.70 6.66(m,2H,Ar),3.92 3.80
(m, 4H, 2   CH2), 3.57 3.52 (m, 2H, CH2), 3.10 (s, 1H, NH),
1.70 1.61 (m, 2H, CH2), 1.45 1.35 (m, 2H, CH2), 0.88 (t, 3H,4576 dx.doi.org/10.1021/jm200488a |J. Med. Chem. 2011, 54, 4559–4580
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J = 7.4 Hz, CH3).
13C NMR (CDCl3): δ 159.2, 157.8, 145.3, 142.8,
129.6,127.3,123.2,116.6,115.0,68.1,44.8,36.9,31.1,19.1,13.7.HRMS
(ESþ) m/z found 391.0821; C19H22N2O5S( M
þ þ H) requires
391.1328.
4-(tert-Butyldimethylsilanyloxy)-4-(2-oxoimidazolidin-1-
yl)benzenesulfonate(58).MethodB:flashchromatography(meth-
ylene chloride to methylene chloride/ethyl acetate 3:1). Yield: 53%.
White solid. Mp: 222 223  C. IR ν: 3227, 1716 cm
 1.
1H NMR
(CDCl3):δ 7.75 7.66 (m, 4H,Ar), 6.83 6.80 (m, 2H,Ar), 6.70 6.68
(m,2H,Ar),5.10(s,1H,NH),4.00 3.95(m,2H,CH2),3.67 3.62(m,
2H, CH2), 0.95 (s, 9H, 3   CH3), 0.16 (s, 6H, 2   CH3).
13C NMR
(CDCl3):δ158.6,154.4,145.2,143.6,129.8,127.7,123.4,120.7,116.6,44.9,
37.1,25.6,18.2, 4.5.HRMS(ESþ)m/zfound449.1561;C21H28N2O5SSi
(M
þ þ H) requires 449.1567.
4-Chlorophenyl-4-(2-oxoimidazolidin-1-yl)benzenesulfo-
nate (59). Method B: flash chromatography (methylene chloride to
methylene chloride/ethyl acetate 8:2). Yield: 89%. White solid. Mp:
179 180  C. IR ν: 3229, 1712 cm
 1.
1H NMR (DMSO-d6): δ 7.84 
7.75 (m, 4H, Ar), 7.51 7.46 (m, 3H, Ar and NH), 7.07 7.04 (m, 2H,
Ar), 3.95 3.90 (m, 2H, CH2), 3.49 3.44 (m, 2H, CH2).
13C NMR
(DMSO-d6): δ 158.2, 131.7, 130.0, 129.5, 124.7, 124.1, 116.4, 115.6,
110.6, 44.2, 36.3. HRMS (ESþ) m/z found 353.0836; C15H13ClN2O4S
(M
þ þ H) requires 353.0363.
4-Fluorophenyl-4-(2-oxoimidazolidin-1-yl)benzenesulfo-
nate (60). Method B: flash chromatography (methylene chloride to
methylene chloride/ethyl acetate 8:2). Yield: 33%. White solid. Mp:
208 209  C. IR ν: 3227, 1714 cm
 1.
1H NMR (CDCl3 and MeOD):
δ 7.65 7.58 (m, 4H, Ar), 6.90 6.83 (m, 4H, Ar), 3.91 3.86 (m, 2H,
CH2), 3.55 3.49 (m, 2H, CH2).
13C NMR (CDCl3 and MeOD):
δ159.1,145.5,129.6,126.8,124.0,123.9,116.6,116.4,116.1,44.8,36.8.
HRMS (ESþ) m/z found 337.0647; C15H13FN2O4S( M
þ þ H)
requires 337.0658.
4-Iodophenyl-4-(2-oxoimidazolidin-1-yl)benzenesulfonate
(61). Method B: flash chromatography (ethyl acetate to ethyl acetate/
methanol 95:5). Yield: 74%. White solid. Mp: 202 204  C. IR ν: 3203,
1710 cm
 1.
1H NMR (DMSO-d6 and CDCl3): δ 7.73 7.70 (m, 2H,
Ar), 7.64 7.55 (m, 4H, Ar), 7.13 (brs, 1H, NH), 6.71 6.68 (m, 2H,
Ar), 3.92 3.87 (m, 2H, CH2), 3.53 3.47 (m, 2H, CH2).
13C NMR
(DMSO-d6 and CDCl3): δ 158.2, 149.0, 145.9, 138.3, 129.1, 125.4,
124.2, 116.1, 91.5, 44.2, 36.4. HRMS (ESþ) m/z found 444.9747;
C15H13IN2O4S( M
þ þ H) requires 444.9719.
4-Nitrophenyl-4-(2-oxoimidazolidin-1-yl)benzenesulfonate
(62). Method B: flash chromatography (methylene chloride to methy-
lenechloride/ethylacetate7:3).Yield:98%.Whitesolid.Mp:195 196 C.
IRν:3267,1704cm
 1.
1HNMR(DMSO-d6):δ8.29(d,2H,J=9.1Hz,
Ar), 7.83 (s, 4H, Ar), 7.46 (s, 1H, NH), 7.35 (d, 2H, J = 9.1 Hz, Ar),
3.96 3.91 (m, 2H, CH2), 3.49 3.44 (m, 2H, CH2).
13C NMR
(DMSO-d6): δ 158.2, 153.4, 146.6, 146.0, 129.6, 125.8, 124.5, 123.4,
116.5, 44.2, 36.3. HRMS (ESþ) m/z found 363.9860; C15H13N3O6S
(M
þ þ H) requires 364.0603.
4-Aminophenyl-4-(2-oxoimidazolidin-1-yl)benzenesulfo-
nate (63). Method C: flash chromatography (methylene chloride to
methylene chloride/methanol 9:1). Yield: 46%. White solid. Mp: 152 
154 C.IRν:3265,1716cm
 1.
1HNMR(DMSO-d6):δ7.81 7.68(m,
4H,Ar),7.40(s,1H,Ar),6.78 6.76(m,1H,Ar),6.62(d,1H,J=8.7Hz,
Ar), 6.44 (d, 1H, J = 8.7 Hz, Ar), 5.20 (s, 1H, NH), 3.95 3.90 (m, 2H,
CH2),3.48 3.41(m,2H,CH2).
13CNMR(DMSO-d6):δ158.3,145.9,
139.1,129.4,122.6,122.3,116.2,114.0,113.3,44.3, 36.3.HRMS(ESþ)
m/z found 333.9906; C15H15N3O4S( M
þ þ H) requires 334.0862.
2-Methylquinolin-8-yl-4-(2-oxoimidazolidin-1-yl)benzene-
sulfonate(64).MethodB:flashchromatography(methylenechloride
tomethylenechloride/methanol9:1).Yield:82%.Mp:234 235 C.IR
ν: 3255, 1724 cm
 1.
1H NMR (DMSO-d6): δ 8.25 (d, 1H, J = 8.4 Hz,
Ar),7.91 7.87(m,1H,Ar),7.82 7.69(m,4H,Ar),7.58 7.51(m,2H,
Ar), 7.41 (d, 1H, J = 8.4 Hz, Ar), 7.36 (s, 1H, NH), 3.89 3.84 (m, 2H,
CH2),3.47 3.41(m,2H,CH2),2.53(s,3H,CH3).
13CNMR(DMSO-
d6):δ159.5,158.2,145.9,144.3,140.2,136.0,129.6,127.7,127.2,126.4,
125.3, 123.0, 122.6, 115.8, 44.3, 36.3, 24.9. HRMS (ESþ) m/z found
384.0133; C19H17N3O4S( M
þ þ H) requires 384.1018.
1H-Indol-5-yl-4-(2-oxoimidazolidin-1-yl)benzenesulfonate
(65). Method B: flash chromatography (methylene chloride to methy-
lenechloride/ethylacetate7:3).Yield:82%.Whitesolid.Mp:226 227 C.
IR ν: 3417, 1712 cm
 1.
1H NMR (DMSO-d6): δ 11.28 (s, 1H, NH),
7.80 7.71(m,4H,Ar),7.43 7.39(m,2H,Ar),7.33 7.30(m,1H,Ar),
7.21 7.20 (m, 1H, Ar), 6.70 6.66 (m, 1H, Ar), 6.43 (brs, 1H, NH),
3.93 3.88 (m, 2H, CH2), 3.47 3.42 (m, 2H, CH2).
13C NMR
(DMSO-d6): δ 158.3, 145.9, 142.5, 134.2, 129.3, 127.6, 127.4, 125.8,
116.3, 115.2, 112.9, 112.0, 101.7, 44.2, 36.3. HRMS (ESþ) m/z found
358.0028; C17H15N3O4S( M
þ þ H) requires 358.0862.
Pyridin-2-yl-4-(2-oxoimidazolidin-1-yl)benzenesulfonate
(66). Method B: not washed with hydrochloric acid; flash chromatog-
raphy (methylene chloride to methylene chloride/ethyl acetate 0:1).
Yield:32%.Whitesolid.Mp:153 155 C.IRν:3228,3117,1695cm
 1.
1H NMR (DMSO-d6): δ 8.31 8.29 (m, 1H, Ar), 8.00 7.95 (m, 1H,
Ar),7.89 7.81(m,4H,Ar),7.53 7.39(m,2H,NHandAr),7.20 7.17
(m, 1H, Ar), 3.96 3.91 (m, 2H, CH2), 3.49 3.44 (m, 2H, CH2).
13C
NMR (DMSO-d6): δ 158.2, 156.4, 148.4, 146.1, 141.1, 129.4, 126.8,
123.4, 116.3, 115.8, 44.3, 36.3. HRMS (ESþ) m/z found 320.0730;
C14H13N3O4S( M
þ þ H) requires 320.0705.
Pyridin-4-yl-4-(2-oxoimidazolidin-1-yl)benzenesulfonate
(67). Method B: not washed with hydrochloric acid; flash chromatog-
raphy (methylenechloride tomethylene chloride/methanol 9:1).Yield:
28%. White solid. Mp: 188 192  C. IR ν: 3226, 3114, 1729 cm
 1.
1H
NMR (DMSO-d6): δ 8.59 (d, 2H, J = 7.0 Hz, Ar), 7.56 7.49 (m, 4H,
Ar), 7.27 (d, 2H, J = 7.0 Hz, Ar), 7.00 (s, 1H, NH), 3.88 3.83 (m, 2H,
CH2),3.44 3.39(m,2H,CH2).
13CNMR(DMSO-d6):δ171.6,158.9,
143.0, 141.4, 140.8, 126.0, 115.7, 114.0, 44.5, 36.5. HRMS (ESþ) m/z
found 320.0730; C14H13N3O4S( M
þ þ H) requires 320.0705.
4-(1H-Imidazol-1-yl)phenyl-4-(2-oxoimidazolidin-1-yl)ben-
zenesulfonate (68). Method B: flash chromatography (ethyl acetate
to ethyl acetate/methanol 9:1). Yield: 74%. White solid. Mp: 206 
208  C. IR ν: 3220, 2910, 2811, 1713 cm
 1.
1H NMR (DMSO-d6):
δ 8.26 (s, 1H, Ar), 7.86 7.78 (m,4H, Ar), 7.74 (s, 1H, Ar), 7.71 (s, 1H,
Ar), 7.68 (s, 1H, Ar), 7.43 (brs, 1H, NH), 7.19 (s, 1H, Ar), 7.16 (s, 1H,
Ar), 7.11 (s, 1H, Ar), 3.95 3.90 (m, 2H, CH2), 3.49 3.44 (m, 2H,
CH2).
13CNMR(DMSO-d6):δ158.2,147.3,146.3,135.7,130.1,129.5,
125.0, 123.6, 121.7, 118.1, 116.4, 44.3, 36.3. HRMS (ESþ) m/z found
385.0567; C18H16N4O4S( M
þ þ H) requires 385.0971.
2-Tolyl-4-[tetrahydro-2-oxopyrimidin-1(2H)-yl]benzenesul-
fonate (69). Method B: flash chromatography (ethyl acetate to ethyl
acetate/methanol 95:5). Yield: 58%. White solid. Mp: 161 163  C. IR
ν:3209,2944, 1657cm
 1.
1HNMR(DMSO-d6):δ7.81 7.65(m, 4H,
Ar),7.32 7.22(m,3H,ArandNH),7.03 7.00(m,2H,Ar),3.76 3.72
(m, 2H, CH2), 3.27 3.23 (m, 2H, CH2), 2.07 (s, 3H, CH3), 2.03 1.98
(m, 2H, CH2).
13C NMR (DMSO-d6): δ 153.7, 149.7, 147.8, 131.8,
131.0, 128.3, 128.3, 127.4, 127.3, 123.5, 121.9, 47.1, 39.7, 22.0, 15.9.
HRMS(ESþ)m/zfound347.1064;C17H18N2O4S(M
þþH)requires
347.1065.
2-Ethylphenyl-4-[tetrahydro-2-oxopyrimidin-1(2H)-yl]ben-
zenesulfonate (70). Method B: flash chromatography (ethyl acetate
toethylacetate/methanol95:5).Yield:69%.Whitesolid.Mp:142 144 C.
IR ν: 3209, 2976, 1655 cm
 1.
1H NMR (DMSO-d6): δ 7.83 7.66 (m,
4H, Ar), 7.37 7.22 (m, 3H, Ar), 7.03 7.00 (m, 2H, Ar and NH), 3.74
(t,2H,J=5.7Hz,CH 2),3.27 3.24(m,2H,CH2),2.49(q,2H,J=7.5Hz,
CH2), 2.00 (quint, 2H, J = 5.7 Hz, CH2), 1.07 (t, 3H, J = 7.5 Hz, CH3).
13CNMR(DMSO-d6):δ153.7,149.7,147.3,136.7,130.2,128.4,128.2,
127.4, 127.3, 123.5, 121.7, 47.1, 39.7, 22.2, 22.0, 14.1. HRMS (ESþ)
m/z found 361.1223; C18H20N2O4S( M
þ þ H) requires 361.1222.4577 dx.doi.org/10.1021/jm200488a |J. Med. Chem. 2011, 54, 4559–4580
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2-Propylphenyl-4-[tetrahydro-2-oxopyrimidin-1(2H)-yl]ben-
zenesulfonate (71). Method B: flash chromatography (methylene
chloride to methylene chloride/methanol 9:1). Yield: 98%. White solid.
Mp:131 132 C.IRν:3223,1955,1667cm
 1.
1HNMR(DMSO-d6):
δ 7.81 7.65 (m, 4H, Ar), 7.33 7.21 (m, 3H, Ar and NH), 7.04 7.01
(m, 2H, Ar), 3.73 (t, 2H, J = 5.6 Hz, CH2), 3.26 3.23 (m, 2H, CH2),
2.42 2.38 (m, 2H, CH2), 1.98 (quint, 2H, J = 5.6 Hz, CH2) 1.48 1.41
(m, 2H, CH2), 0.82 (t, 3H, J = 7.3 Hz, CH3).
13C NMR (DMSO-d6):
δ 153.7, 149.7, 147.6, 135.1, 130.8, 128.5, 128.2, 127.4, 127.3, 123.5,
121.8, 47.1, 39.7, 31.2, 22.6, 22.0, 13.8. HRMS (ESþ) m/z found
375.1172; C19H22N2O4S( M
þ þ H) requires 375.1378.
2,4-Dimethylphenyl-4-[tetrahydro-2-oxopyrimidin-1(2H)-
yl]benzenesulfonate (72). Method B: flash chromatography (ethyl
acetate to ethyl acetate/methanol 95:5). Yield: 62%. White solid. Mp:
161 163  C. IR ν: 3228, 2949, 1684 cm
 1.
1H NMR (DMSO-d6):
δ 7.79 7.65 (m, 4H, Ar), 7.10 (s, 1H, NH), 7.03 7.02 (m, 2H, Ar),
6.88 6.86 (m, 1H, Ar), 3.74 (t, 2H, J = 5.6 Hz, CH2), 3.27 3.24 (m,
2H, CH2), 2.27 (s, 3H, CH3), 2.01 1.96 (m, 5H, CH2 and CH3).
13C
NMR (DMSO-d6): δ 153.7, 149.6, 145.7, 136.6, 132.2, 130.6, 128.4,
128.3, 127.7, 123.5, 121.7, 47.1, 39.7, 22.0, 20.3, 15.8. HRMS (ESþ) m/z
found 361.1222; C18H20N2O4S( M
þ þ H) requires 361.1222.
2,4,5-Trichlorophenyl-4-[tetrahydro-2-oxopyrimidin-1(2H)-
yl]benzenesulfonate(73).MethodB:flashchromatography(meth-
ylene chloride to methylene chloride/methanol 9:1). Yield: 88%. White
solid. Mp: 199 201  C. IR ν: 3221, 3094, 1673 cm
 1.
1H NMR
(DMSO-d6): δ 8.05 (s, 1H, NH or Ar), 7.85 7.66 (m, 4H, Ar), 7.61 (s,
1H, NHor Ar), 7.04 (brs,1H, NHor Ar), 3.74 (t,2H, J=5.6Hz, CH2),
3.26 3.23 (m, 2H, CH2), 1.99 (quint, 2H, J = 5.6 Hz, CH2).
13C NMR
(DMSO-d6): δ 153.6, 150.3, 143.9, 131.7, 131.0, 130.7, 128.8, 126.8,
126.6,125.7,123.4,47.0,39.7,22.0.HRMS(ESþ)m/zfound434.9741;
C16H13Cl3N2O4S( M
þ þ H) requires 434.9740.
2,4,6-Trichlorophenyl-4-[tetrahydro-2-oxopyrimidin-1(2H)-
yl]benzenesulfonate (74). Method B: flash chromatography (ethyl
acetate to ethyl acetate/methanol 95:5). Yield: 68%. White solid. Mp:
219 221  C. IR ν: 3230, 3077, 1672 cm
 1.
1H NMR (DMSO-d6): δ
7.95 7.70(m,6H,Ar),7.05(s,1H,NH),3.77(t,2H,J=5.6Hz,CH2),
3.28 3.25(m,2H,CH2),2.04 1.96(m,2H,CH2).
13CNMR(DMSO-
d6):δ153.7,150.2,141.7,132.5,130.1,129.6,128.7,128.6,123.4,47.1,39.7,
22.0.HRMS(ESþ)m/zfound434.9742;C16H13Cl3N2O4S(M
þþH)
requires 434.9740.
3-Tolyl-4-[tetrahydro-2-oxopyrimidin-1(2H)-yl]benzenesul-
fonate (75). Method B: flash chromatography (ethyl acetate to ethyl
acetate/methanol 95:5). Yield: 57%. White solid. Mp: 145 147  C. IR
ν: 3209, 1675 cm
 1.
1H NMR (DMSO-d6): δ 7.79 7.63 (m, 4H, Ar),
7.30 7.14(m,2H,Ar),7.01(brs,1H,NH),6.93(s,1H,Ar),6.83 6.81
(m, 1H, Ar), 3.75 3.72 (m, 2H, CH2), 3.27 3.24 (m, 2H, CH2), 2.29
(s, 3H, CH3), 2.01 1.97 (m, 2H, CH2).
13C NMR (DMSO-d6): δ 153.7,
149.6, 149.1, 140.0, 129.7, 128.4, 128.0, 127.8, 123.4, 122.5, 118.8, 47.0,
39.7, 22.0, 20.8. HRMS (ESþ) m/z found 347.1066; C17H18N2O4S
(M
þ þ H) requires 347.1065.
3-Methoxyphenyl-4-[tetrahydro-2-oxopyrimidin-1(2H)-
yl]benzenesulfonate(76).MethodB:flashchromatography(meth-
ylene chloride to methylene chloride/methanol 9:1). Yield: 72%. White
solid. Mp: 132 134  C. IR ν: 3218, 3081, 1667 cm
 1.
1H NMR
(DMSO-d6): δ 7.79 7.62 (m, 4H, Ar), 7.33 7.27 (m, 1H, Ar), 7.01
(brs, 1H, NH), 6.91 6.88 (m, 1H, Ar), 6.64 6.62 (m, 1H, Ar),
6.57 6.56 (m, 1H, Ar), 3.72 (t, 2H, J = 5.8 Hz, CH2), 3.68 (s, 3H,
CH3), 3.25 3.224 (m, 2H, CH2), 1.99 1.96 (m, 2H, CH2).
13C NMR
(DMSO-d6): δ 160.1, 153.7, 150.0, 149.6, 130.5, 128.4, 127.6, 123.4,
113.9, 113.2, 107.9, 55.5, 47.0, 39.7, 22.0. HRMS (ESþ) m/z found
363.1013; C17H18N2O5S( M
þ þ H) requires 363.1014.
3-Fluorophenyl-4-[tetrahydro-2-oxopyrimidin-1(2H)-yl]ben-
zenesulfonate (77). Method B: flash chromatography (methylene
chloride to methylene chloride/methanol 9:1). Yield: 74%. White solid.
Mp:149 150 C.IRν:3209,3076,1670cm
 1.
1HNMR(DMSO-d6):
δ 7.80 7.63 (m, 4H, Ar), 7.54 7.42 (m, 1H, Ar), 7.25 7.19 (m, 1H,
Ar),7.05 7.01(m,1H,Ar),6.94 6.91(m,1H,Ar),3.74 3.60(m,2H,
CH2), 3.24 (t, 2H, J = 5.7 Hz, CH2), 1.97 (quint, 2H, J = 5.7 Hz, CH2).
13CNMR(DMSO-d6):δ153.7,149.8,131.5,131.3,128.5,127.1,125.5,
123.9, 123.4, 118.3, 118.3, 114.7, 114.4, 110.3, 110.0, 47.0, 22.1, 22.0.
HRMS (ESþ) m/z found 351.0816; C16H15FN2O4S( M
þ þ H)
requires 351.0815.
3,4,5-Trimethoxyphenyl-4-[tetrahydro-2-oxopyrimidin-
1(2H)-yl]benzenesulfonate (78). Method B: flash chromatogra-
phy (methylene chloride to methylene chloride/ethyl acetate 7:3). Yield:
75%. White solid. Mp: 218 220  C. IR ν: 3430, 1697 cm
 1.
1H NMR
(DMSO-d6):δ7.81 7.62(m,4H,Ar),7.00(brs,1H,NH),6.28(s,2H,
Ar), 3.72 (t, 2H, J = 5.6 HZ, CH2), 3.64 (s, 6H, 2   CH3), 3.63 (s, 3H,
CH3), 3.28 3.23 (m, 2H, CH2), 2.02 1.95 (m, 2H, CH2).
13C NMR
(DMSO-d6): δ 153.7, 153.1, 149.8, 145.0, 136.3, 128.7, 127.6, 123.7,
100.0, 60.1, 56.1, 47.1, 39.7, 22.0. HRMS (ESþ) m/z found 423.1227;
C19H22N2O7S( M
þ þ H) requires 423.1226.
4-Tolyl-4-[tetrahydro-2-oxopyrimidin-1(2H)-yl]benzenesul-
fonate (79). Method B: flash chromatography (ethyl acetate to ethyl
acetate/methanol 95:5). Yield: 72%. White solid. Mp: 204 205  C. IR
ν:3213,3067, 1667cm
 1.
1HNMR(DMSO-d6):δ7.77 7.63(m, 4H,
Ar), 7.21 7.18 (m, 2H, Ar), 7.02 (brs, 1H, NH), 6.95 6.92 (m, 2H,
Ar), 3.74 3.71 (m, 2H, CH2), 3.28 3.23 (m, 2H, CH2), 2.29 (s, 3H,
CH3),2.02 1.95(m,2H,CH2).
13CNMR(DMSO-d6):δ153.7,149.5,
147.0, 136.9, 130.4, 128.4, 127.7, 123.3, 121.8, 47.0, 39.7, 22.0, 20.4.
HRMS(ESþ)m/zfound347.1063;C17H18N2O4S(M
þþH)requires
347.1065.
4-Chlorophenyl-4-[tetrahydro-2-oxopyrimidin-1(2H)-yl]ben-
zenesulfonate (80). Method B: flash chromatography (ethyl acetate
toethylacetate/methanol95:5).Yield:77%.Whitesolid.Mp:190 192 C.
IR ν: 3231, 3062, 1648 cm
 1.
1H NMR (DMSO-d6): δ 7.79 7.65 (m,
4H, Ar), 7.50 7.47 (m, 2H, Ar), 7.12 7.09 (m, 2H, Ar), 7.03 (brs, 1H,
NH), 3.74 (t, 2H, J = 5.4 Hz, CH2), 3.27 3.24 (m, 2H, CH2), 2.03 
1.96(m,2H,CH2).
13CNMR(DMSO-d6):δ153.7,149.8,147.8,131.8,
130.1, 128.5, 127.1, 124.0, 123.3, 47.0, 39.7, 22.0. HRMS (ESþ) m/z
found 367.0529; C16H15ClN2O4S( M
þ þ H) requires 367.0519.
4-Fluorophenyl-4-[tetrahydro-2-oxopyrimidin-1(2H)-yl]ben-
zenesulfonate (81). Method B: flash chromatography (ethyl acetate
toethylacetate/methanol95:5).Yield:80%.Whitesolid.Mp:172 174 C.
IR ν: 3224, 3088, 1666 cm
 1.
1H NMR (DMSO-d6): δ 7.78 7.64 (m,
4H, Ar), 7.29 7.23 (m, 2H, Ar), 7.13 7.09 (m, 2H, Ar), 7.03 (s, 1H,
NH), 3.75 3.72 (m, 2H, CH2), 3.28 3.23 (m, 2H, CH2), 2.02 1.97
(m, 2H, CH2).
13C NMR (DMSO-d6): δ 153.7, 149.7, 145.2, 145.2,
128.5, 127.2, 124.2, 124.1, 123.3, 116.9, 116.6, 47.0, 39.7, 22.0. HRMS
(ESþ) m/z found 351.0814; C16H15FN2O4S( M
þ þ H) requires
351.0815.
General Procedure for the Synthesis of Compounds 82
and 83. 2-Chloroethyl isocyanate or 3-chloropropyl isocyanate (1.2
equiv) was added dropwise to a cold solution (ice bath) of the aniline
(1.0 equiv) in dry methylene chloride (15 mL per g of aniline). The ice
bath was then removed, and the reaction mixture was stirred at room
temperature for 24 h. After completion of the reaction, the solvent was
evaporated under reduced pressure to give white solid, which was
triturated twice with cold hexanes/ether 10:1.
1-(2-Chloroethyl)-3-phenylurea (82). Yield: 99%. Mp: 108 
110  C. IR ν: 3304, 1637 cm
 1.
1H NMR (DMSO-d6): δ 8.69 (s, 1H,
NH), 7.44 7.41 (m, 2H, Ar), 7.27 7.22 (m, 2H, Ar), 6.95 6.90 (m,
1H, Ar), 6.45 (t, 1H, J = 5.1 Hz, NH), 3.68 (t, 2H, J = 6.1 Hz, CH2),
3.48 3.42 (m, 2H, CH2).
13C NMR (CDCl3 and MeOD): δ 156.5,
138.9, 128.8, 122.7, 119.5, 44.0, 41.7.
1-(3-Chloropropyl)-3-phenylurea (83). Yield: 93%. Mp: 115 
117  C. IR ν: 3329, 1633 cm
 1.
1H NMR (DMSO-d6): δ 8.45 (s, 1H,
NH), 7.43 7.40 (m, 2H, Ar), 7.26 7.21 (m, 2H, Ar), 6.93 6.88 (m,4578 dx.doi.org/10.1021/jm200488a |J. Med. Chem. 2011, 54, 4559–4580
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1H, Ar), 6.27 (t, 1H, J = 5.6 Hz, NH), 3.68 (t, 2H, J = 6.5 Hz, CH2),
3.27 3.21 (m, 2H, CH2), 1.90 (apparent quint, 2H, J = 6.5 Hz, CH2).
13C NMR (DMSO-d6): δ 155.3, 140.5, 128.6, 121.1, 117.7, 43.1,
36.6, 32.7.
Preparation of Compounds 84 and 85. Sodium hydride
(3 equiv) was added slowly to a cold solution of compound 82 or 83
(1 equiv) in tetrahydrofuran under dry nitrogen atmosphere. The ice
bathwasthenremovedafter30min,andthereactionmixturewasstirred
at room temperature for 5 h. The reaction was quenched at 0  C with
water and diluted with ethyl acetate. The organic layer was washed with
water and brine, dried over sodium sulfate, filtered, and concentrated in
vacuotoafford84or85aswhitesolids,whichwereusedwithoutfurther
purification.
1-Phenylimidazolidin-2-one (84). Yield: 98%. Compound 84
was also synthesized using method described by Neville.
44 Briefly,
triphosgene (12.2 mmol) was dissolved in 40 mL of tetrahydrofuran
and cooled at 0  C. To the resulting solution was added 36.7 mmol of
N-phenylethylenediamine dissolved in 65 mL of tetrahydrofuran and
7.7 mL of triethylamine over a period of 30 min. A white solid im-
mediately precipitated, and the reaction was complete after 5 min. The
reactionmixturewasquenchedwithwateranddilutedwithethylacetate.
The organic layer was washed with water and brine, dried over sodium
sulfate, filtered, and concentrated in vacuo. The residue was purified by
flash chromatography (methylene chloride to methylene chloride/ethyl
acetate3:10)toaffordawhitesolid.Yield:80%.Mp:154 156 C.IRν:
3240, 1680 cm
 1.
1H NMR (DMSO-d6): δ 7.58 7.55 (m, 2H, Ar),
7.34 7.29(m,2H,Ar),7.02 6.95(m,2H,ArandNH),3.88 3.83(m,
2H, CH2), 3.44 3.39 (m, 2H, CH2).
13C NMR (CDCl3): δ 160.2,
140.2, 128.8, 122.7, 117.9, 45.3, 37.5.
Tetrahydro-3-phenylpyrimidin-2(1H)-one (85). Yield: 95%.
Mp:198 200 C.IRν:3216,3060,1643cm
 1.
1HNMR(DMSO-d6):
δ 7.32 7.28 (m, 4H, Ar), 7.14 7.10 (m, 1H, Ar), 6.58 (s, 1H, NH),
3.63 (t, 2H, J = 5.7 Hz, CH2), 3.27 3.22 (m, 2H, CH2), 1.96 (apparent
quint, 2H, J = 5.7 Hz, CH2).
13C NMR (DMSO-d6): δ 154.4, 144.4,
128.1, 125.1, 124.2, 48.0, 22.2.
PreparationofCompounds86and87. To1.5mL (23.1mmol)
ofchlorosulfonic acidin 3mL ofcarbon tetrachloride at0  C was added
slowly (3.1 mmol) to compound 84 or 85. The reaction was almost
completed after 2 h at 0  C. The reaction mixture was poured slowly
onto ice water and filtered to collect the solid. The white solid was
dried under vacuum.
4-(2-Oxoimidazolidin-1-yl)benzene-1-sulfonyl Chloride (86).
Yield: 56%. Mp: 257 259  C. IR ν: 3232, 1711 cm
 1.
1H NMR (DMSO-
d6):δ7.57 7.51(m,4H,Ar),3.88 3.82(m,2H,CH2),3.44 3.38(m,
2H, CH2).
13C NMR (DMSO-d6): δ 158.9, 141.2, 140.5, 126.1, 115.8,
44.5, 36.5.
4-(Tetrahydro-2-oxopyrimidin-1(2H)-yl)benzene-1-sulfo-
nyl Chloride (87). Yield: 32%. Mp: 262 266  C. IR ν: 3093,
1667 cm
 1.
1H NMR (DMSO-d6): δ 7.56 (d, 2H, J = 8.3 Hz, Ar),
7.28 (d, 2H, J = 8.3 Hz, Ar), 3.66 3.61 (m, 2H, CH2), 3.41 3.23 (m,
2H, CH2), 2.03 1.92 (m, 2H, CH2).
13C NMR (DMSO-d6): δ 154.6,
143.9, 143.8, 125.7, 124.4, 48.0, 21.7.
CoMFA and CoMSIA: Superimposition of PIB-SOs. All cal-
culationswereperformedonSGIOnyx3800supercomputersystemand
Windows system. SYBYL molecular modeling software package was
usedtoperformtheQSARanalysis.
64InCoMSIAstudies,ansp
3carbon
atom with a unit positive charge was used as a probe to evaluate five
interaction fields: steric, electrostatic, hydrophobic, hydrogen bond
donor, and hydrogen bond acceptor. All aligned molecules were set in
a Cartesian coordinates box. The probe was used to calculate the field
potentialsintheboxwitha2Ågridresolution.Inordertogetanoptimal
QSAR models, other different descriptors were used to optimize the
QSAR equation. Those descriptors involved in optimizing the QSAR
analysis are molecular weight (MW), molecular volume (V), molar
refractivity (MR), polar volume (PV), polar surface area (PSA), logP
value (LogP), and the similarity data of each compound to the
hypothesis. An integer parameter was used to describe the five- and
six-member rings of imidazolidinone and the adjacent phenyl moieties.
In CoMFA studies, Tripos standard fields were used as CoMFA field
classesandansp
3carbonatomwithaunitpositivechargewasusedasthe
probe toevaluate stericandelectrostatic potentials ateverylatticepoint.
Theresolutionofthegridwas2Å.Distancemethodwasusedtocontrol
the form of the Coulombic electrostatic energy calculation. A 30 kcal/mol
cutoff was used forsteric and electrostatic field values. Inaddition to the
CoMFA fields, all descriptors used in optimizing the CoMSIA models
were also used in optimizing CoMFA models.
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